

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

F1_R2

C Number: C99024C
Lock Date: 06/29/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF Androstenedione

MALE RATS

Organ

Adrenal Cortex
Brain

Kidney

Liver

Liver: Hepatocyte

Lung

Lymph Node, Mesenteric

Lymph Node: Pancreatic

Mesentery

Nose

Nose: Respiratory Epithelium

Pancreas

Preputial Gland

Prostate: Epithelium

Spleen

Spleen: Lymphoid Follicle

Thymus

Thyroid Gland: C-Cell

Thyroid Gland: Follicle

Morphology

Hyperplasia Focal

Compression

Hemorrhage

Necrosis

Infarct

Nephropathy

Basophilic Focus

Clear Cell Focus

Degeneration Cystic

Eosinophilic Focus

Infiltration Cellular Mixed Cell

Necrosis Focal

Vacuolization Cytoplasmic

Inflammation Chronic

Hyperplasia

Pigmentation

Hyperplasia

Accessory Spleen

Foreign Body

Hyperplasia

Atrophy

Cyst

Cyst

Inflammation Chronic

Hyperplasia

Fibrosis

Hemorrhage

Hyperplasia

Hyperplasia Lymphoid

Hyperplasia

Cyst

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Androstenedione

Tongue

Hyperplasia

FEMALE RATS

Organ

Adrenal Cortex

Clitoral Gland

Eye

Eye: Retina

Islets, Pancreatic

Kidney: Renal Tubule

Liver

Liver: Bile Duct

Liver: Kupffer Cell

Lymph Node, Mesenteric

Lymph Node: Mediastinal

Mammary Gland

Nose

Nose: Respiratory Epithelium

Pancreas

Pancreas: Acinus

Pituitary Gland: Pars Distalis

Pituitary Gland: Rathke's Cleft

Spleen

Spleen: Lymphoid Follicle

Stomach, Glandular

Morphology

Degeneration Fatty

Hypertrophy Focal

Hyperplasia

Cataract

Degeneration

Hyperplasia

Accumulation, Hyaline Droplet

Basophilic Focus

Eosinophilic Focus

Infiltration Cellular Mixed Cell

Hyperplasia

Pigmentation

Hyperplasia

Hyperplasia Lymphoid

Cyst

Hyperplasia

Inflammation

Inflammation Chronic

Hyperplasia

Atrophy

Infiltration Cellular Lymphocyte

Cytoplasmic Alteration

Hyperplasia Focal

Angiectasis

Cyst

Pigmentation

Hyperplasia

Edema

Erosion

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Accessory Adrenal Cortical Nodule**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/40.03	3/44.49	1/42.72	1/43.53
POLY-3 PERCENT (g)	2.5%	6.7%	2.3%	2.3%
TERMINAL (d)	0/21 (0%)	3/33 (9%)	1/29 (3%)	0/27 (0%)
FIRST INCIDENCE	387	729 (T)	729 (T)	589

STATISTICAL TESTS

POLY 3	P=0.427N	P=0.344	P=0.746N	P=0.742N
POLY 1.5	P=0.438N	P=0.325	P=0.753N	P=0.749N
POLY 6	P=0.416N	P=0.371	P=0.736N	P=0.733N
COCH-ARM / FISHERS	P=0.456N	P=0.309	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.456N	P=0.193	P=0.481N	P=0.476N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Degeneration Fatty**

LESION RATES

OVERALL (a)	22/50 (44%)	27/50 (54%)	25/50 (50%)	21/50 (42%)
POLY-3 RATE (b)	22/44.11	27/46.60	25/46.18	21/46.10
POLY-3 PERCENT (g)	49.9%	57.9%	54.1%	45.6%
TERMINAL (d)	8/21 (38%)	18/33 (55%)	13/29 (45%)	10/27 (37%)
FIRST INCIDENCE	540	621	521	563

STATISTICAL TESTS

POLY 3	P=0.247N	P=0.284	P=0.422	P=0.420N
POLY 1.5	P=0.262N	P=0.248	P=0.389	P=0.445N
POLY 6	P=0.249N	P=0.333	P=0.461	P=0.408N
COCH-ARM / FISHERS	P=0.311N	P=0.212	P=0.344	P=0.500N
MAX-ISO-POLY-3	P=0.343N	P=0.223	P=0.343	P=0.341N

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/39.18	0/44.49	0/42.72	0/43.06
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	5/50 (10%)	4/50 (8%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	5/39.20	4/44.87	3/42.72	1/43.06
POLY-3 PERCENT (g)	12.8%	8.9%	7%	2.3%
TERMINAL (d)	4/21 (19%)	3/33 (9%)	3/29 (10%)	1/27 (4%)
FIRST INCIDENCE	724	621	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.064N	P=0.416N	P=0.309N	P=0.080N
POLY 1.5	P=0.067N	P=0.454N	P=0.330N	P=0.088N
POLY 6	P=0.064N	P=0.365N	P=0.281N	P=0.072N
COCH-ARM / FISHERS	P=0.073N	P=0.500N	P=0.357N	P=0.102N
MAX-ISO-POLY-3	P=0.074N	P=0.298N	P=0.202N	P=0.039N*

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
Hypertrophy Focal**

LESION RATES

OVERALL (a)	3/50 (6%)	3/50 (6%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	3/39.33	3/44.49	2/43.29	4/43.60
POLY-3 PERCENT (g)	7.6%	6.7%	4.6%	9.2%
TERMINAL (d)	2/21 (10%)	3/33 (9%)	1/29 (3%)	3/27 (11%)
FIRST INCIDENCE	689	729 (T)	547	563

STATISTICAL TESTS

POLY 3	P=0.434	P=0.605N	P=0.456N	P=0.556
POLY 1.5	P=0.426	P=0.631N	P=0.475N	P=0.534
POLY 6	P=0.437	P=0.569N	P=0.431N	P=0.579
COCH-ARM / FISHERS	P=0.406	P=0.661N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.504	P=0.440N	P=0.294N	P=0.403

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	5/50 (10%)	8/50 (16%)	6/50 (12%)	10/50 (20%)
POLY-3 RATE (b)	5/40.03	8/44.81	6/42.88	10/43.98
POLY-3 PERCENT (g)	12.5%	17.9%	14%	22.7%
TERMINAL (d)	1/21 (5%)	7/33 (21%)	5/29 (17%)	6/27 (22%)
FIRST INCIDENCE	619	641	687	659

STATISTICAL TESTS

POLY 3	P=0.158	P=0.351	P=0.549	P=0.172
POLY 1.5	P=0.149	P=0.317	P=0.528	P=0.156
POLY 6	P=0.163	P=0.397	P=0.574	P=0.190
COCH-ARM / FISHERS	P=0.130	P=0.277	P=0.500	P=0.131
MAX-ISO-POLY-3	P=0.188	P=0.259	P=0.421	P=0.119

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Bone Marrow
 Hyperplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	4/50 (8%)	4/50 (8%)	7/50 (14%)
POLY-3 RATE (b)	4/40.12	4/45.30	4/43.89	7/45.21
POLY-3 PERCENT (g)	10%	8.8%	9.1%	15.5%
TERMINAL (d)	1/21 (5%)	2/33 (6%)	1/29 (3%)	0/27 (0%)
FIRST INCIDENCE	526	540	547	589

STATISTICAL TESTS

POLY 3	P=0.199	P=0.575N	P=0.594N	P=0.332
POLY 1.5	P=0.188	P=0.606N	P=0.616N	P=0.303
POLY 6	P=0.209	P=0.534N	P=0.563N	P=0.369
COCH-ARM / FISHERS	P=0.167	P=0.643N	P=0.643N	P=0.262
MAX-ISO-POLY-3	P=0.318	P=0.431N	P=0.448N	P=0.238

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Bone Marrow
 Myelofibrosis**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/39.34	2/44.81	0/42.72	0/43.06
POLY-3 PERCENT (g)	2.5%	4.5%	0%	0%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	688	641	---	---

STATISTICAL TESTS

POLY 3	P=0.204N	P=0.545	P=0.484N	P=0.482N
POLY 1.5	P=0.209N	P=0.525	P=0.491N	P=0.489N
POLY 6	P=0.199N	P=0.572	P=0.474N	P=0.475N
COCH-ARM / FISHERS	P=0.218N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.199N	P=0.329	P=0.158N	P=0.158N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Brain
 Compression**

LESION RATES

OVERALL (a)	13/50 (26%)	8/50 (16%)	7/50 (14%)	9/50 (18%)
POLY-3 RATE (b)	13/41.61	8/46.14	7/43.92	9/45.89
POLY-3 PERCENT (g)	31.2%	17.3%	15.9%	19.6%
TERMINAL (d)	5/21 (24%)	3/33 (9%)	3/29 (10%)	1/27 (4%)
FIRST INCIDENCE	547	551	593	544

STATISTICAL TESTS

POLY 3	P=0.257N	P=0.099N	P=0.075N	P=0.155N
POLY 1.5	P=0.268N	P=0.125N	P=0.087N	P=0.184N
POLY 6	P=0.252N	P=0.073N	P=0.063N	P=0.130N
COCH-ARM / FISHERS	P=0.296N	P=0.163N	P=0.105N	P=0.235N
MAX-ISO-POLY-3	P=0.107N	P=0.071N	P=0.049N*	P=0.114N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Brain
 Hemorrhage**

LESION RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	3/39.94	0/44.49	2/43.34	4/44.40
POLY-3 PERCENT (g)	7.5%	0%	4.6%	9%
TERMINAL (d)	1/21 (5%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	589	---	593	587

STATISTICAL TESTS

POLY 3	P=0.212	P=0.100N	P=0.463N	P=0.558
POLY 1.5	P=0.211	P=0.108N	P=0.479N	P=0.535
POLY 6	P=0.208	P=0.091N	P=0.441N	P=0.582
COCH-ARM / FISHERS	P=0.206	P=0.121N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.233	P=0.037N*	P=0.298N	P=0.405

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Brain
 Necrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/39.18	0/44.49	0/42.72	2/44.01
POLY-3 PERCENT (g)	0%	0%	0%	4.5%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	---	---	---	587

STATISTICAL TESTS

POLY 3	P=0.045*	(e)	(e)	P=0.264
POLY 1.5	P=0.045*	(e)	(e)	P=0.253
POLY 6	P=0.045*	(e)	(e)	P=0.276
COCH-ARM / FISHERS	P=0.044*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.055	(e)	(e)	P=0.101

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Eye
 Cataract**

LESION RATES

OVERALL (a)	1/48 (2%)	0/46 (0%)	1/50 (2%)	2/49 (4%)
POLY-3 RATE (b)	1/37.82	0/42.55	1/42.83	2/42.24
POLY-3 PERCENT (g)	2.6%	0%	2.3%	4.7%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	2/27 (7%)
FIRST INCIDENCE	688	---	701	729 (T)

STATISTICAL TESTS

POLY 3	P=0.256	P=0.477N	P=0.733N	P=0.538
POLY 1.5	P=0.260	P=0.490N	P=0.741N	P=0.527
POLY 6	P=0.248	P=0.461N	P=0.722N	P=0.549
COCH-ARM / FISHERS	P=0.259	P=0.511N	P=0.742N	P=0.508
MAX-ISO-POLY-3	P=0.278	P=0.161N	P=0.466N	P=0.321

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Eye: Retina
 Degeneration

LESION RATES

OVERALL (a)	1/48 (2%)	1/46 (2%)	1/50 (2%)	4/49 (8%)
POLY-3 RATE (b)	1/37.78	1/42.55	1/42.83	4/42.24
POLY-3 PERCENT (g)	2.7%	2.4%	2.3%	9.5%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	4/27 (15%)
FIRST INCIDENCE	701	729 (T)	701	729 (T)

STATISTICAL TESTS

POLY 3	P=0.068	P=0.733N	P=0.732N	P=0.213
POLY 1.5	P=0.068	P=0.749N	P=0.741N	P=0.203
POLY 6	P=0.066	P=0.713N	P=0.721N	P=0.223
COCH-ARM / FISHERS	P=0.066	P=0.742	P=0.742N	P=0.187
MAX-ISO-POLY-3	P=0.106	P=0.468N	P=0.465N	P=0.115

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Eye: Sclera
Metaplasia Osseous

LESION RATES

OVERALL (a)	0/48 (0%)	3/46 (7%)	2/50 (4%)	1/49 (2%)
POLY-3 RATE (b)	0/37.67	3/43.02	2/42.88	1/42.24
POLY-3 PERCENT (g)	0%	7%	4.7%	2.4%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	1/29 (3%)	1/27 (4%)
FIRST INCIDENCE	---	641	687	729 (T)

STATISTICAL TESTS

POLY 3	P=0.573N	P=0.144	P=0.267	P=0.523
POLY 1.5	P=0.589N	P=0.129	P=0.258	P=0.516
POLY 6	P=0.560N	P=0.165	P=0.279	P=0.530
COCH-ARM / FISHERS	P=0.617N	P=0.113	P=0.258	P=0.505
MAX-ISO-POLY-3	P=0.241	P=0.062	P=0.102	P=0.185

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Heart
 Cardiomyopathy**

LESION RATES

OVERALL (a)	47/50 (94%)	47/50 (94%)	48/50 (96%)	48/50 (96%)
POLY-3 RATE (b)	47/48.75	47/49.63	48/49.73	48/49.76
POLY-3 PERCENT (g)	96.4%	94.7%	96.5%	96.5%
TERMINAL (d)	21/21 (100%)	33/33 (100%)	29/29 (100%)	26/27 (96%)
FIRST INCIDENCE	387	224	387	544

STATISTICAL TESTS

POLY 3	P=0.548	P=0.533N	P=0.720	P=0.724
POLY 1.5	P=0.481	P=0.591N	P=0.623	P=0.626
POLY 6	P=0.640	P=0.469N	P=0.699N	P=0.667N
COCH-ARM / FISHERS	P=0.397	P=0.661N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.622	P=0.325N	P=0.486	P=0.495

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Heart
 Thrombosis**

LESION RATES

OVERALL (a)	6/50 (12%)	3/50 (6%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	6/40.34	3/44.56	3/43.32	2/43.27
POLY-3 PERCENT (g)	14.9%	6.7%	6.9%	4.6%
TERMINAL (d)	0/21 (0%)	2/33 (6%)	0/29 (0%)	1/27 (4%)
FIRST INCIDENCE	619	712	615	673

STATISTICAL TESTS

POLY 3	P=0.128N	P=0.194N	P=0.206N	P=0.110N
POLY 1.5	P=0.128N	P=0.215N	P=0.221N	P=0.118N
POLY 6	P=0.132N	P=0.171N	P=0.188N	P=0.104N
COCH-ARM / FISHERS	P=0.133N	P=0.243N	P=0.243N	P=0.134N
MAX-ISO-POLY-3	P=0.080N	P=0.123N	P=0.129N	P=0.060N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Intestine Large, Colon
 Edema

LESION RATES

OVERALL (a)	2/44 (5%)	1/43 (2%)	4/47 (9%)	0/44 (0%)
POLY-3 RATE (b)	2/35.23	1/40.78	4/41.73	0/39.18
POLY-3 PERCENT (g)	5.7%	2.5%	9.6%	0%
TERMINAL (d)	0/20 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	651	705	615	---

STATISTICAL TESTS

POLY 3	P=0.218N	P=0.449N	P=0.417	P=0.214N
POLY 1.5	P=0.221N	P=0.473N	P=0.396	P=0.222N
POLY 6	P=0.221N	P=0.420N	P=0.447	P=0.205N
COCH-ARM / FISHERS	P=0.231N	P=0.509N	P=0.371	P=0.247N
MAX-ISO-POLY-3	P=0.198N	P=0.255N	P=0.277	P=0.075N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Islets, Pancreatic
 Hyperplasia**

LESION RATES

OVERALL (a)	5/50 (10%)	4/50 (8%)	2/50 (4%)	9/50 (18%)
POLY-3 RATE (b)	5/40.28	4/45.73	2/42.90	9/44.06
POLY-3 PERCENT (g)	12.4%	8.8%	4.7%	20.4%
TERMINAL (d)	1/21 (5%)	1/33 (3%)	0/29 (0%)	6/27 (22%)
FIRST INCIDENCE	552	568	701	563

STATISTICAL TESTS

POLY 3	P=0.076	P=0.421N	P=0.190N	P=0.243
POLY 1.5	P=0.076	P=0.456N	P=0.201N	P=0.224
POLY 6	P=0.072	P=0.376N	P=0.176N	P=0.261
COCH-ARM / FISHERS	P=0.074	P=0.500N	P=0.218N	P=0.194
MAX-ISO-POLY-3	P=0.081	P=0.302N	P=0.107N	P=0.172

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Cyst**

LESION RATES

OVERALL (a)	0/49 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/38.50	0/44.49	0/42.72	1/43.06
POLY-3 PERCENT (g)	0%	0%	0%	2.3%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	1/27 (4%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.218	(e)	(e)	P=0.522
POLY 1.5	P=0.217	(e)	(e)	P=0.515
POLY 6	P=0.218	(e)	(e)	P=0.529
COCH-ARM / FISHERS	P=0.212	(e)	(e)	P=0.505
MAX-ISO-POLY-3	P=0.161	(e)	(e)	P=0.184

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Infarct**

LESION RATES

OVERALL (a)	3/49 (6%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/39.16	1/44.81	0/42.72	0/43.06
POLY-3 PERCENT (g)	7.7%	2.2%	0%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	547	641	---	---

STATISTICAL TESTS

POLY 3	P=0.069N	P=0.258N	P=0.103N	P=0.102N
POLY 1.5	P=0.068N	P=0.276N	P=0.108N	P=0.107N
POLY 6	P=0.073N	P=0.236N	P=0.097N	P=0.098N
COCH-ARM / FISHERS	P=0.067N	P=0.301N	P=0.117N	P=0.117N
MAX-ISO-POLY-3	P=0.022N*	P=0.137N	P=0.037N*	P=0.037N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Nephropathy**

LESION RATES

OVERALL (a)	42/49 (86%)	48/50 (96%)	46/50 (92%)	44/50 (88%)
POLY-3 RATE (b)	42/46.39	48/48.50	46/47.95	44/48.60
POLY-3 PERCENT (g)	90.5%	99%	95.9%	90.5%
TERMINAL (d)	20/21 (95%)	33/33 (100%)	29/29 (100%)	26/27 (96%)
FIRST INCIDENCE	456	540	442	544

STATISTICAL TESTS

POLY 3	P=0.295N	P=0.052	P=0.232	P=0.649N
POLY 1.5	P=0.347N	P=0.046*	P=0.233	P=0.593
POLY 6	P=0.290N	P=0.077	P=0.243	P=0.653N
COCH-ARM / FISHERS	P=0.484N	P=0.075	P=0.251	P=0.484
MAX-ISO-POLY-3	P=0.221N	P=0.016*	P=0.116	P=0.498N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	1/49 (2%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/38.93	1/44.49	0/42.72	1/43.22
POLY-3 PERCENT (g)	2.6%	2.3%	0%	2.3%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	604	729 (T)	---	687

STATISTICAL TESTS

POLY 3	P=0.673N	P=0.730N	P=0.481N	P=0.737N
POLY 1.5	P=0.673N	P=0.742N	P=0.488N	P=0.744N
POLY 6	P=0.674N	P=0.715N	P=0.474N	P=0.731N
COCH-ARM / FISHERS	P=0.676N	P=0.747N	P=0.495N	P=0.747N
MAX-ISO-POLY-3	P=0.519N	P=0.463N	P=0.157N	P=0.471N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Necrosis**

LESION RATES

OVERALL (a)	1/49 (2%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/38.76	1/44.56	2/43.14	0/43.06
POLY-3 PERCENT (g)	2.6%	2.2%	4.6%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	659	712	674	---

STATISTICAL TESTS

POLY 3	P=0.325N	P=0.729N	P=0.537	P=0.479N
POLY 1.5	P=0.328N	P=0.741N	P=0.524	P=0.485N
POLY 6	P=0.326N	P=0.712N	P=0.555	P=0.474N
COCH-ARM / FISHERS	P=0.339N	P=0.747N	P=0.508	P=0.495N
MAX-ISO-POLY-3	P=0.306N	P=0.462N	P=0.320	P=0.157N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Pigmentation**

LESION RATES

OVERALL (a)	5/49 (10%)	2/50 (4%)	6/50 (12%)	6/50 (12%)
POLY-3 RATE (b)	5/39.47	2/45.10	6/43.38	6/43.84
POLY-3 PERCENT (g)	12.7%	4.4%	13.8%	13.7%
TERMINAL (d)	1/21 (5%)	0/33 (0%)	1/29 (3%)	4/27 (15%)
FIRST INCIDENCE	619	641	674	563

STATISTICAL TESTS

POLY 3	P=0.303	P=0.165N	P=0.567	P=0.574
POLY 1.5	P=0.303	P=0.184N	P=0.544	P=0.552
POLY 6	P=0.292	P=0.144N	P=0.595	P=0.590
COCH-ARM / FISHERS	P=0.289	P=0.210N	P=0.514	P=0.514
MAX-ISO-POLY-3	P=0.366	P=0.098N	P=0.439	P=0.447

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Basophilic Focus

LESION RATES

OVERALL (a)	17/50 (34%)	29/50 (58%)	29/50 (58%)	33/50 (66%)
POLY-3 RATE (b)	17/41.41	29/45.97	29/44.81	33/45.56
POLY-3 PERCENT (g)	41.1%	63.1%	64.7%	72.4%
TERMINAL (d)	13/21 (62%)	25/33 (76%)	24/29 (83%)	24/27 (89%)
FIRST INCIDENCE	456	540	547	544

STATISTICAL TESTS

POLY 3	P=0.005**	P=0.026*	P=0.017*	P<0.001**
POLY 1.5	P=0.005**	P=0.017*	P=0.014*	P<0.001**
POLY 6	P=0.006**	P=0.048*	P=0.026*	P<0.001**
COCH-ARM / FISHERS	P=0.004**	P=0.013*	P=0.013*	P<0.001**
MAX-ISO-POLY-3	P=0.002**	P=0.019*	P=0.012*	P<0.001**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Clear Cell Focus

LESION RATES

OVERALL (a)	13/50 (26%)	21/50 (42%)	23/50 (46%)	17/50 (34%)
POLY-3 RATE (b)	13/39.18	21/44.82	23/42.72	17/43.06
POLY-3 PERCENT (g)	33.2%	46.9%	53.8%	39.5%
TERMINAL (d)	13/21 (62%)	20/33 (61%)	23/29 (79%)	17/27 (63%)
FIRST INCIDENCE	729 (T)	639	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.533	P=0.140	P=0.040*	P=0.355
POLY 1.5	P=0.497	P=0.100	P=0.034*	P=0.315
POLY 6	P=0.550	P=0.216	P=0.052	P=0.400
COCH-ARM / FISHERS	P=0.422	P=0.069	P=0.030*	P=0.257
MAX-ISO-POLY-3	P=0.182	P=0.109	P=0.028*	P=0.281

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Degeneration Cystic

LESION RATES

OVERALL (a)	10/50 (20%)	3/50 (6%)	12/50 (24%)	7/50 (14%)
POLY-3 RATE (b)	10/39.47	3/44.56	12/43.09	7/43.47
POLY-3 PERCENT (g)	25.3%	6.7%	27.9%	16.1%
TERMINAL (d)	7/21 (33%)	2/33 (6%)	10/29 (35%)	5/27 (19%)
FIRST INCIDENCE	689	712	659	666

STATISTICAL TESTS

POLY 3	P=0.450N	P=0.018N*	P=0.496	P=0.220N
POLY 1.5	P=0.455N	P=0.025N*	P=0.455	P=0.249N
POLY 6	P=0.458N	P=0.012N*	P=0.555	P=0.190N
COCH-ARM / FISHERS	P=0.479N	P=0.036N*	P=0.405	P=0.298N
MAX-ISO-POLY-3	P=0.243N	P=0.011N*	P=0.399	P=0.159N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Eosinophilic Focus

LESION RATES

OVERALL (a)	3/50 (6%)	10/50 (20%)	7/50 (14%)	13/50 (26%)
POLY-3 RATE (b)	3/39.18	10/44.49	7/43.57	13/43.90
POLY-3 PERCENT (g)	7.7%	22.5%	16.1%	29.6%
TERMINAL (d)	3/21 (14%)	10/33 (30%)	6/29 (21%)	11/27 (41%)
FIRST INCIDENCE	729 (T)	729 (T)	387	605

STATISTICAL TESTS

POLY 3	P=0.021*	P=0.056	P=0.202	P=0.010**
POLY 1.5	P=0.018*	P=0.046*	P=0.183	P=0.008**
POLY 6	P=0.023*	P=0.075	P=0.229	P=0.012*
COCH-ARM / FISHERS	P=0.014*	P=0.036*	P=0.159	P=0.006**
MAX-ISO-POLY-3	P=0.013*	P=0.037*	P=0.132	P=0.006**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Hepatodiaphragmatic Nodule

LESION RATES

OVERALL (a)	7/50 (14%)	8/50 (16%)	7/50 (14%)	10/50 (20%)
POLY-3 RATE (b)	7/41.23	8/45.56	7/43.78	10/44.04
POLY-3 PERCENT (g)	17%	17.6%	16%	22.7%
TERMINAL (d)	3/21 (14%)	4/33 (12%)	5/29 (17%)	6/27 (22%)
FIRST INCIDENCE	456	551	521	589

STATISTICAL TESTS

POLY 3	P=0.273	P=0.584	P=0.567N	P=0.348
POLY 1.5	P=0.269	P=0.545	P=0.588N	P=0.329
POLY 6	P=0.269	P=0.589N	P=0.539N	P=0.367
COCH-ARM / FISHERS	P=0.251	P=0.500	P=0.613N	P=0.298
MAX-ISO-POLY-3	P=0.406	P=0.472	P=0.451N	P=0.260

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Infiltration Cellular Mixed Cell

LESION RATES

OVERALL (a)	10/50 (20%)	3/50 (6%)	11/50 (22%)	4/50 (8%)
POLY-3 RATE (b)	10/40.68	3/44.87	11/43.76	4/43.06
POLY-3 PERCENT (g)	24.6%	6.7%	25.1%	9.3%
TERMINAL (d)	8/21 (38%)	2/33 (6%)	9/29 (31%)	4/27 (15%)
FIRST INCIDENCE	456	621	547	729 (T)

STATISTICAL TESTS

POLY 3	P=0.141N	P=0.020N*	P=0.577	P=0.054N
POLY 1.5	P=0.140N	P=0.027N*	P=0.541	P=0.061N
POLY 6	P=0.150N	P=0.014N*	P=0.572N	P=0.046N*
COCH-ARM / FISHERS	P=0.150N	P=0.036N*	P=0.500	P=0.074N
MAX-ISO-POLY-3	P=0.049N*	P=0.012N*	P=0.476	P=0.031N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Mixed Cell Focus

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	1/39.33	2/44.49	1/42.72	4/43.06
POLY-3 PERCENT (g)	2.5%	4.5%	2.3%	9.3%
TERMINAL (d)	0/21 (0%)	2/33 (6%)	1/29 (3%)	4/27 (15%)
FIRST INCIDENCE	689	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.115	P=0.543	P=0.742N	P=0.206
POLY 1.5	P=0.112	P=0.523	P=0.750N	P=0.196
POLY 6	P=0.115	P=0.568	P=0.731N	P=0.216
COCH-ARM / FISHERS	P=0.105	P=0.500	P=0.753N	P=0.181
MAX-ISO-POLY-3	P=0.138	P=0.327	P=0.476N	P=0.109

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Necrosis Focal

LESION RATES

OVERALL (a)	4/50 (8%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	4/40.07	0/44.49	1/42.93	1/43.48
POLY-3 PERCENT (g)	10%	0%	2.3%	2.3%
TERMINAL (d)	1/21 (5%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	612	---	674	607

STATISTICAL TESTS

POLY 3	P=0.229N	P=0.048N*	P=0.157N	P=0.154N
POLY 1.5	P=0.222N	P=0.053N	P=0.167N	P=0.163N
POLY 6	P=0.240N	P=0.042N*	P=0.146N	P=0.146N
COCH-ARM / FISHERS	P=0.219N	P=0.059N	P=0.181N	P=0.181N
MAX-ISO-POLY-3	P=0.034N*	P=0.019N*	P=0.078N	P=0.077N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Bile Duct
 Hyperplasia

LESION RATES

OVERALL (a)	44/50 (88%)	44/50 (88%)	40/50 (80%)	43/50 (86%)
POLY-3 RATE (b)	44/47.26	44/47.75	40/46.36	43/48.04
POLY-3 PERCENT (g)	93.1%	92.2%	86.3%	89.5%
TERMINAL (d)	19/21 (91%)	33/33 (100%)	27/29 (93%)	25/27 (93%)
FIRST INCIDENCE	464	551	521	544

STATISTICAL TESTS

POLY 3	P=0.322N	P=0.595N	P=0.200N	P=0.385N
POLY 1.5	P=0.344N	P=0.618N	P=0.190N	P=0.411N
POLY 6	P=0.351N	P=0.609N	P=0.256N	P=0.425N
COCH-ARM / FISHERS	P=0.436N	P=0.620N	P=0.207N	P=0.500N
MAX-ISO-POLY-3	P=0.275N	P=0.419N	P=0.112N	P=0.245N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Hepatocyte
 Hyperplasia

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	1/39.80	0/44.49	2/43.04	2/43.06
POLY-3 PERCENT (g)	2.5%	0%	4.7%	4.6%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	1/29 (3%)	2/27 (7%)
FIRST INCIDENCE	526	---	641	729 (T)

STATISTICAL TESTS

POLY 3	P=0.279	P=0.478N	P=0.527	P=0.527
POLY 1.5	P=0.280	P=0.488N	P=0.515	P=0.517
POLY 6	P=0.274	P=0.464N	P=0.545	P=0.537
COCH-ARM / FISHERS	P=0.273	P=0.500N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.305	P=0.158N	P=0.310	P=0.310

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Hepatocyte
 Vacuolization Cytoplasmic

LESION RATES

OVERALL (a)	25/50 (50%)	18/50 (36%)	14/50 (28%)	9/50 (18%)
POLY-3 RATE (b)	25/45.49	18/47.36	14/45.75	9/44.57
POLY-3 PERCENT (g)	55%	38%	30.6%	20.2%
TERMINAL (d)	7/21 (33%)	7/33 (21%)	3/29 (10%)	4/27 (15%)
FIRST INCIDENCE	387	540	521	587

STATISTICAL TESTS

POLY 3	P<0.001N**	P=0.073N	P=0.013N*	P<0.001N**
POLY 1.5	P<0.001N**	P=0.091N	P=0.015N*	P<0.001N**
POLY 6	P<0.001N**	P=0.054N	P=0.011N*	P<0.001N**
COCH-ARM / FISHERS	P<0.001N**	P=0.113N	P=0.020N*	P<0.001N**
MAX-ISO-POLY-3	P<0.001N**	P=0.051N	P=0.008N**	P<0.001N**

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver: Kupffer Cell
Pigmentation**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/39.18	0/44.49	0/42.72	0/43.06
POLY-3 PERCENT (g)	2.6%	0%	0%	0%
TERMINAL (d)	1/21 (5%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.417N	P=0.475N	P=0.483N	P=0.481N
POLY 1.5	P=0.407N	P=0.486N	P=0.490N	P=0.488N
POLY 6	P=0.430N	P=0.459N	P=0.472N	P=0.474N
COCH-ARM / FISHERS	P=0.394N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.124N	P=0.158N	P=0.158N	P=0.158N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	17/50 (34%)	17/50 (34%)	18/50 (36%)	18/50 (36%)
POLY-3 RATE (b)	17/42.65	17/45.67	18/44.45	18/44.12
POLY-3 PERCENT (g)	39.9%	37.2%	40.5%	40.8%
TERMINAL (d)	7/21 (33%)	14/33 (42%)	15/29 (52%)	16/27 (59%)
FIRST INCIDENCE	456	551	442	544

STATISTICAL TESTS

POLY 3	P=0.467	P=0.486N	P=0.564	P=0.552
POLY 1.5	P=0.473	P=0.530N	P=0.539	P=0.539
POLY 6	P=0.428	P=0.437N	P=0.583	P=0.541
COCH-ARM / FISHERS	P=0.453	P=0.583N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.642	P=0.400N	P=0.475	P=0.463

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	0/39.18	0/44.49	1/42.72	3/43.65
POLY-3 PERCENT (g)	0%	0%	2.3%	6.9%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	1/29 (3%)	2/27 (7%)
FIRST INCIDENCE	---	---	729 (T)	544

STATISTICAL TESTS

POLY 3	P=0.023*	(e)	P=0.517	P=0.139
POLY 1.5	P=0.022*	(e)	P=0.510	P=0.131
POLY 6	P=0.023*	(e)	P=0.528	P=0.147
COCH-ARM / FISHERS	P=0.021*	(e)	P=0.500	P=0.121
MAX-ISO-POLY-3	P=0.035*	(e)	P=0.179	P=0.055

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung: Alveolar Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	6/50 (12%)	7/50 (14%)	8/50 (16%)	4/50 (8%)
POLY-3 RATE (b)	6/40.63	7/44.82	8/43.54	4/43.73
POLY-3 PERCENT (g)	14.8%	15.6%	18.4%	9.2%
TERMINAL (d)	1/21 (5%)	6/33 (18%)	5/29 (17%)	2/27 (7%)
FIRST INCIDENCE	554	639	547	563

STATISTICAL TESTS

POLY 3	P=0.231N	P=0.576	P=0.440	P=0.323N
POLY 1.5	P=0.240N	P=0.542	P=0.417	P=0.339N
POLY 6	P=0.231N	P=0.617	P=0.469	P=0.310N
COCH-ARM / FISHERS	P=0.265N	P=0.500	P=0.387	P=0.370N
MAX-ISO-POLY-3	P=0.303N	P=0.458	P=0.333	P=0.221N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Ectasia**

LESION RATES

OVERALL (a)	3/50 (6%)	5/50 (10%)	7/50 (14%)	5/50 (10%)
POLY-3 RATE (b)	3/39.75	5/44.58	7/43.35	5/44.11
POLY-3 PERCENT (g)	7.6%	11.2%	16.2%	11.3%
TERMINAL (d)	0/21 (0%)	4/33 (12%)	4/29 (14%)	2/27 (7%)
FIRST INCIDENCE	659	708	631	589

STATISTICAL TESTS

POLY 3	P=0.437	P=0.421	P=0.193	P=0.414
POLY 1.5	P=0.417	P=0.391	P=0.177	P=0.392
POLY 6	P=0.452	P=0.458	P=0.215	P=0.437
COCH-ARM / FISHERS	P=0.376	P=0.357	P=0.159	P=0.357
MAX-ISO-POLY-3	P=0.331	P=0.295	P=0.124	P=0.289

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node, Mesenteric Hemorrhage

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/39.18	0/44.49	2/43.14	0/43.06
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	---	---	674	---

STATISTICAL TESTS

POLY 3	P=0.702N	(e)	P=0.259	(e)
POLY 1.5	P=0.706N	(e)	P=0.249	(e)
POLY 6	P=0.702N	(e)	P=0.274	(e)
COCH-ARM / FISHERS	P=0.716	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.289	(e)	P=0.097	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Hyperplasia**

LESION RATES

OVERALL (a)	25/50 (50%)	13/50 (26%)	25/50 (50%)	19/50 (38%)
POLY-3 RATE (b)	25/42.20	13/46.40	25/45.73	19/43.53
POLY-3 PERCENT (g)	59.2%	28%	54.7%	43.6%
TERMINAL (d)	18/21 (86%)	8/33 (24%)	16/29 (55%)	16/27 (59%)
FIRST INCIDENCE	456	540	442	648

STATISTICAL TESTS

POLY 3	P=0.383N	P=0.002N**	P=0.411N	P=0.098N
POLY 1.5	P=0.362N	P=0.004N**	P=0.489N	P=0.118N
POLY 6	P=0.438N	P<0.001N**	P=0.298N	P=0.079N
COCH-ARM / FISHERS	P=0.365N	P=0.011N*	P=0.579N	P=0.157N
MAX-ISO-POLY-3	P=0.082N	P<0.001N**	P=0.332N	P=0.067N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/39.20	2/44.81	1/43.49	1/43.30
POLY-3 PERCENT (g)	2.6%	4.5%	2.3%	2.3%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	724	641	442	666

STATISTICAL TESTS

POLY 3	P=0.525N	P=0.546	P=0.737N	P=0.738N
POLY 1.5	P=0.533N	P=0.525	P=0.747N	P=0.747N
POLY 6	P=0.519N	P=0.575	P=0.724N	P=0.729N
COCH-ARM / FISHERS	P=0.548N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.590N	P=0.330	P=0.471N	P=0.472N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Pigmentation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/39.18	0/44.49	0/42.72	2/43.06
POLY-3 PERCENT (g)	0%	0%	0%	4.6%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	2/27 (7%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.044*	(e)	(e)	P=0.258
POLY 1.5	P=0.044*	(e)	(e)	P=0.250
POLY 6	P=0.043*	(e)	(e)	P=0.267
COCH-ARM / FISHERS	P=0.044*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.051	(e)	(e)	P=0.096

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node: Mediastinal
 Ectasia**

LESION RATES

OVERALL (a)	1/25 (4%)	0/18 (0%)	2/16 (13%)	0/13 (0%)
POLY-3 RATE (b)	1/21.33	0/16.16	2/13.87	0/10.97
POLY-3 PERCENT (g)	4.7%	0%	14.4%	0%
TERMINAL (d)	0/11 (0%)	0/9 (0%)	0/4 (0%)	0/5 (0%)
FIRST INCIDENCE	554	---	442	---

STATISTICAL TESTS

POLY 3	P=0.604N	P=0.556N	P=0.348	P=0.632N
POLY 1.5	P=0.599N	P=0.559N	P=0.347	P=0.630N
POLY 6	P=0.615N	P=0.552N	P=0.346	P=0.637N
COCH-ARM / FISHERS	P=0.594N	P=0.581N	P=0.334	P=0.658N
MAX-ISO-POLY-3	P=0.424N	P=0.204N	P=0.180	P=0.268N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node: Mediastinal Hemorrhage

LESION RATES

OVERALL (a)	0/25 (0%)	1/18 (6%)	1/16 (6%)	0/13 (0%)
POLY-3 RATE (b)	0/20.77	1/16.16	1/13.19	0/10.97
POLY-3 PERCENT (g)	0%	6.2%	7.6%	0%
TERMINAL (d)	0/11 (0%)	1/9 (11%)	0/4 (0%)	0/5 (0%)
FIRST INCIDENCE	---	729 (T)	674	---

STATISTICAL TESTS

POLY 3	P=0.698N	P=0.449	P=0.409	(e)
POLY 1.5	P=0.698N	P=0.443	P=0.409	(e)
POLY 6	P=0.700N	P=0.457	P=0.408	(e)
COCH-ARM / FISHERS	P=0.703N	P=0.419	P=0.390	(e)
MAX-ISO-POLY-3	P=0.419	P=0.135	P=0.126	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node: Mediastinal
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	3/25 (12%)	3/18 (17%)	0/16 (0%)	0/13 (0%)
POLY-3 RATE (b)	3/21.67	3/16.76	0/12.98	0/10.97
POLY-3 PERCENT (g)	13.8%	17.9%	0%	0%
TERMINAL (d)	0/11 (0%)	1/9 (11%)	0/4 (0%)	0/5 (0%)
FIRST INCIDENCE	589	641	---	---

STATISTICAL TESTS

POLY 3	P=0.113N	P=0.541	P=0.219N	P=0.258N
POLY 1.5	P=0.110N	P=0.526	P=0.212N	P=0.254N
POLY 6	P=0.122N	P=0.558	P=0.232N	P=0.269N
COCH-ARM / FISHERS	P=0.109N	P=0.497	P=0.216N	P=0.273N
MAX-ISO-POLY-3	P=0.173N	P=0.371	P=0.108N	P=0.133N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node: Pancreatic
 Ectasia

LESION RATES

OVERALL (a)	3/25 (12%)	1/18 (6%)	2/16 (13%)	0/13 (0%)
POLY-3 RATE (b)	3/21.32	1/16.16	2/13.05	0/10.97
POLY-3 PERCENT (g)	14.1%	6.2%	15.3%	0%
TERMINAL (d)	1/11 (9%)	1/9 (11%)	1/4 (25%)	0/5 (0%)
FIRST INCIDENCE	651	729 (T)	712	---

STATISTICAL TESTS

POLY 3	P=0.237N	P=0.406N	P=0.651	P=0.253N
POLY 1.5	P=0.233N	P=0.414N	P=0.658	P=0.252N
POLY 6	P=0.246N	P=0.400N	P=0.637	P=0.261N
COCH-ARM / FISHERS	P=0.228N	P=0.438N	P=0.659	P=0.273N
MAX-ISO-POLY-3	P=0.219N	P=0.234N	P=0.464	P=0.129N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node: Pancreatic Hemorrhage

LESION RATES

OVERALL (a)	1/25 (4%)	0/18 (0%)	1/16 (6%)	0/13 (0%)
POLY-3 RATE (b)	1/20.79	0/16.16	1/13.19	0/10.97
POLY-3 PERCENT (g)	4.8%	0%	7.6%	0%
TERMINAL (d)	0/11 (0%)	0/9 (0%)	0/4 (0%)	0/5 (0%)
FIRST INCIDENCE	724	---	674	---

STATISTICAL TESTS

POLY 3	P=0.555N	P=0.551N	P=0.657	P=0.628N
POLY 1.5	P=0.552N	P=0.557N	P=0.657	P=0.628N
POLY 6	P=0.560N	P=0.544N	P=0.657	P=0.630N
COCH-ARM / FISHERS	P=0.550N	P=0.581N	P=0.634	P=0.658N
MAX-ISO-POLY-3	P=0.429N	P=0.198N	P=0.382	P=0.262N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node: Pancreatic
 Hyperplasia**

LESION RATES

OVERALL (a)	7/25 (28%)	0/18 (0%)	3/16 (19%)	2/13 (15%)
POLY-3 RATE (b)	7/21.16	0/16.16	3/13.83	2/10.97
POLY-3 PERCENT (g)	33.1%	0%	21.7%	18.2%
TERMINAL (d)	6/11 (55%)	0/9 (0%)	1/4 (25%)	2/5 (40%)
FIRST INCIDENCE	619	---	442	729 (T)

STATISTICAL TESTS

POLY 3	P=0.392N	P=0.010N**	P=0.364N	P=0.317N
POLY 1.5	P=0.386N	P=0.012N*	P=0.371N	P=0.317N
POLY 6	P=0.404N	P=0.008N**	P=0.363N	P=0.326N
COCH-ARM / FISHERS	P=0.382N	P=0.015N*	P=0.388N	P=0.329N
MAX-ISO-POLY-3	P=0.163N	P=0.004N**	P=0.252N	P=0.219N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mammary Gland
 Cyst**

LESION RATES

OVERALL (a)	8/48 (17%)	4/50 (8%)	4/50 (8%)	11/50 (22%)
POLY-3 RATE (b)	8/38.02	4/45.48	4/43.04	11/45.01
POLY-3 PERCENT (g)	21%	8.8%	9.3%	24.4%
TERMINAL (d)	6/20 (30%)	1/33 (3%)	3/29 (10%)	6/27 (22%)
FIRST INCIDENCE	554	621	641	563

STATISTICAL TESTS

POLY 3	P=0.122	P=0.100N	P=0.119N	P=0.458
POLY 1.5	P=0.120	P=0.124N	P=0.135N	P=0.409
POLY 6	P=0.118	P=0.073N	P=0.099N	P=0.518
COCH-ARM / FISHERS	P=0.112	P=0.159N	P=0.159N	P=0.341
MAX-ISO-POLY-3	P=0.135	P=0.069N	P=0.077N	P=0.365

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mammary Gland
 Hyperplasia**

LESION RATES

OVERALL (a)	38/48 (79%)	37/50 (74%)	33/50 (66%)	42/50 (84%)
POLY-3 RATE (b)	38/46.46	37/49.05	33/47.76	42/49.11
POLY-3 PERCENT (g)	81.8%	75.4%	69.1%	85.5%
TERMINAL (d)	15/20 (75%)	22/33 (67%)	16/29 (55%)	21/27 (78%)
FIRST INCIDENCE	387	224	442	544

STATISTICAL TESTS

POLY 3	P=0.240	P=0.303N	P=0.110N	P=0.412
POLY 1.5	P=0.232	P=0.328N	P=0.112N	P=0.388
POLY 6	P=0.253	P=0.266N	P=0.101N	P=0.451
COCH-ARM / FISHERS	P=0.226	P=0.358N	P=0.109N	P=0.361
MAX-ISO-POLY-3	P=0.181	P=0.225N	P=0.071N	P=0.308

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Mesentery
 Accessory Spleen

LESION RATES

OVERALL (a)	4/18 (22%)	1/13 (8%)	0/12 (0%)	3/18 (17%)
POLY-3 RATE (b)	4/15.01	1/11.79	0/10.01	3/15.84
POLY-3 PERCENT (g)	26.7%	8.5%	0%	19%
TERMINAL (d)	1/8 (13%)	1/7 (14%)	0/6 (0%)	2/11 (18%)
FIRST INCIDENCE	540	729 (T)	---	589

STATISTICAL TESTS

POLY 3	P=0.565N	P=0.241N	P=0.103N	P=0.468N
POLY 1.5	P=0.564N	P=0.254N	P=0.104N	P=0.477N
POLY 6	P=0.567N	P=0.234N	P=0.107N	P=0.467N
COCH-ARM / FISHERS	P=0.563N	P=0.285N	P=0.112N	P=0.500N
MAX-ISO-POLY-3	P=0.180N	P=0.123N	P=0.046N*	P=0.312N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mesentery: Fat
 Necrosis**

LESION RATES

OVERALL (a)	13/18 (72%)	10/13 (77%)	10/12 (83%)	15/18 (83%)
POLY-3 RATE (b)	13/16.50	10/12.40	10/11.82	15/17.53
POLY-3 PERCENT (g)	78.8%	80.7%	84.6%	85.6%
TERMINAL (d)	6/8 (75%)	6/7 (86%)	6/6 (100%)	9/11 (82%)
FIRST INCIDENCE	387	629	521	587

STATISTICAL TESTS

POLY 3	P=0.393	P=0.641	P=0.540	P=0.471
POLY 1.5	P=0.345	P=0.601	P=0.476	P=0.411
POLY 6	P=0.471	P=0.680	P=0.622	P=0.556
COCH-ARM / FISHERS	P=0.290	P=0.552	P=0.403	P=0.345
MAX-ISO-POLY-3	P=0.481	P=0.449	P=0.349	P=0.298

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Nose
 Foreign Body

LESION RATES

OVERALL (a)	5/50 (10%)	13/50 (26%)	5/50 (10%)	0/50 (0%)
POLY-3 RATE (b)	5/39.93	13/45.51	5/43.44	0/43.06
POLY-3 PERCENT (g)	12.5%	28.6%	11.5%	0%
TERMINAL (d)	2/21 (10%)	8/33 (24%)	2/29 (7%)	0/27 (0%)
FIRST INCIDENCE	589	629	631	---

STATISTICAL TESTS

POLY 3	P=0.002N**	P=0.058	P=0.577N	P=0.024N*
POLY 1.5	P=0.003N**	P=0.044*	P=0.601N	P=0.026N*
POLY 6	P=0.002N**	P=0.083	P=0.544N	P=0.022N*
COCH-ARM / FISHERS	P=0.005N**	P=0.033*	P=0.630N	P=0.028N*
MAX-ISO-POLY-3	P=0.004N**	P=0.042*	P=0.444N	P=0.009N**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Nose
 Inflammation**

LESION RATES

OVERALL (a)	3/50 (6%)	4/50 (8%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	3/40.03	4/44.85	1/42.88	1/43.30
POLY-3 PERCENT (g)	7.5%	8.9%	2.3%	2.3%
TERMINAL (d)	0/21 (0%)	3/33 (9%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	547	629	687	666

STATISTICAL TESTS

POLY 3	P=0.144N	P=0.562	P=0.280N	P=0.277N
POLY 1.5	P=0.149N	P=0.534	P=0.291N	P=0.288N
POLY 6	P=0.142N	P=0.598	P=0.266N	P=0.268N
COCH-ARM / FISHERS	P=0.158N	P=0.500	P=0.309N	P=0.309N
MAX-ISO-POLY-3	P=0.200N	P=0.410	P=0.145N	P=0.144N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Nose
 Inflammation Chronic**

LESION RATES

OVERALL (a)	4/50 (8%)	3/50 (6%)	5/50 (10%)	1/50 (2%)
POLY-3 RATE (b)	4/39.77	3/44.58	5/42.93	1/43.06
POLY-3 PERCENT (g)	10.1%	6.7%	11.7%	2.3%
TERMINAL (d)	3/21 (14%)	2/33 (6%)	4/29 (14%)	1/27 (4%)
FIRST INCIDENCE	540	708	674	729 (T)

STATISTICAL TESTS

POLY 3	P=0.145N	P=0.438N	P=0.548	P=0.154N
POLY 1.5	P=0.149N	P=0.466N	P=0.527	P=0.164N
POLY 6	P=0.146N	P=0.400N	P=0.578	P=0.145N
COCH-ARM / FISHERS	P=0.159N	P=0.500N	P=0.500	P=0.181N
MAX-ISO-POLY-3	P=0.166N	P=0.302N	P=0.410	P=0.077N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Nose: Respiratory Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	8/50 (16%)	11/50 (22%)	7/50 (14%)	3/50 (6%)
POLY-3 RATE (b)	8/40.10	11/45.42	7/43.44	3/43.06
POLY-3 PERCENT (g)	20%	24.2%	16.1%	7%
TERMINAL (d)	4/21 (19%)	7/33 (21%)	4/29 (14%)	3/27 (11%)
FIRST INCIDENCE	547	629	631	729 (T)

STATISTICAL TESTS

POLY 3	P=0.028N*	P=0.416	P=0.432N	P=0.075N
POLY 1.5	P=0.030N*	P=0.363	P=0.462N	P=0.083N
POLY 6	P=0.027N*	P=0.489	P=0.390N	P=0.068N
COCH-ARM / FISHERS	P=0.038N*	P=0.306	P=0.500N	P=0.100N
MAX-ISO-POLY-3	P=0.043N*	P=0.327	P=0.330N	P=0.043N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas
 Atrophy**

LESION RATES

OVERALL (a)	17/50 (34%)	30/50 (60%)	19/50 (38%)	21/50 (42%)
POLY-3 RATE (b)	17/42.92	30/46.33	19/44.74	21/44.75
POLY-3 PERCENT (g)	39.6%	64.8%	42.5%	46.9%
TERMINAL (d)	7/21 (33%)	25/33 (76%)	13/29 (45%)	14/27 (52%)
FIRST INCIDENCE	387	568	547	587

STATISTICAL TESTS

POLY 3	P=0.463N	P=0.011*	P=0.478	P=0.314
POLY 1.5	P=0.477N	P=0.008**	P=0.449	P=0.298
POLY 6	P=0.465N	P=0.017*	P=0.518	P=0.324
COCH-ARM / FISHERS	P=0.515N	P=0.008**	P=0.418	P=0.268
MAX-ISO-POLY-3	P=0.209	P=0.008**	P=0.391	P=0.245

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas
 Cyst**

LESION RATES

OVERALL (a)	5/50 (10%)	3/50 (6%)	7/50 (14%)	0/50 (0%)
POLY-3 RATE (b)	5/39.77	3/44.49	7/43.49	0/43.06
POLY-3 PERCENT (g)	12.6%	6.7%	16.1%	0%
TERMINAL (d)	4/21 (19%)	3/33 (9%)	4/29 (14%)	0/27 (0%)
FIRST INCIDENCE	540	729 (T)	621	---

STATISTICAL TESTS

POLY 3	P=0.040N*	P=0.296N	P=0.442	P=0.024N*
POLY 1.5	P=0.042N*	P=0.323N	P=0.414	P=0.026N*
POLY 6	P=0.040N*	P=0.261N	P=0.485	P=0.021N*
COCH-ARM / FISHERS	P=0.049N*	P=0.357N	P=0.380	P=0.028N*
MAX-ISO-POLY-3	P=0.040N*	P=0.195N	P=0.330	P=0.009N**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas
 Infiltration Cellular Lymphocyte**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/39.18	0/44.49	0/42.72	1/43.06
POLY-3 PERCENT (g)	0%	0%	0%	2.3%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	1/27 (4%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.217	(e)	(e)	P=0.519
POLY 1.5	P=0.216	(e)	(e)	P=0.512
POLY 6	P=0.217	(e)	(e)	P=0.526
COCH-ARM / FISHERS	P=0.211	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.157	(e)	(e)	P=0.181

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas: Acinus
 Cytoplasmic Alteration**

LESION RATES

OVERALL (a)	4/50 (8%)	3/50 (6%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	4/40.72	3/45.50	2/43.09	2/43.36
POLY-3 PERCENT (g)	9.8%	6.6%	4.6%	4.6%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	547	540	659	663

STATISTICAL TESTS

POLY 3	P=0.276N	P=0.440N	P=0.311N	P=0.308N
POLY 1.5	P=0.276N	P=0.467N	P=0.322N	P=0.318N
POLY 6	P=0.283N	P=0.406N	P=0.296N	P=0.300N
COCH-ARM / FISHERS	P=0.281N	P=0.500N	P=0.339N	P=0.339N
MAX-ISO-POLY-3	P=0.284N	P=0.303N	P=0.186N	P=0.185N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas: Acinus
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	1/39.18	3/44.49	3/42.72	2/43.48
POLY-3 PERCENT (g)	2.6%	6.7%	7%	4.6%
TERMINAL (d)	1/21 (5%)	3/33 (9%)	3/29 (10%)	1/27 (4%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	607

STATISTICAL TESTS

POLY 3	P=0.584	P=0.352	P=0.336	P=0.536
POLY 1.5	P=0.567	P=0.330	P=0.323	P=0.522
POLY 6	P=0.599	P=0.382	P=0.356	P=0.552
COCH-ARM / FISHERS	P=0.536	P=0.309	P=0.309	P=0.500
MAX-ISO-POLY-3	P=0.404	P=0.201	P=0.185	P=0.319

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Angiectasis**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/49 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/39.47	1/44.49	0/42.10	2/43.31
POLY-3 PERCENT (g)	2.5%	2.3%	0%	4.6%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	1/27 (4%)
FIRST INCIDENCE	651	729 (T)	---	663

STATISTICAL TESTS

POLY 3	P=0.354	P=0.733N	P=0.487N	P=0.532
POLY 1.5	P=0.351	P=0.746N	P=0.495N	P=0.520
POLY 6	P=0.354	P=0.717N	P=0.477N	P=0.545
COCH-ARM / FISHERS	P=0.343	P=0.753N	P=0.505N	P=0.500
MAX-ISO-POLY-3	P=0.319	P=0.467N	P=0.159N	P=0.315

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Cyst**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	1/49 (2%)	4/50 (8%)
POLY-3 RATE (b)	2/39.59	3/45.02	1/42.10	4/43.31
POLY-3 PERCENT (g)	5.1%	6.7%	2.4%	9.2%
TERMINAL (d)	1/21 (5%)	2/33 (6%)	1/29 (3%)	2/27 (7%)
FIRST INCIDENCE	612	568	729 (T)	676

STATISTICAL TESTS

POLY 3	P=0.292	P=0.558	P=0.479N	P=0.379
POLY 1.5	P=0.287	P=0.532	P=0.491N	P=0.363
POLY 6	P=0.294	P=0.592	P=0.461N	P=0.395
COCH-ARM / FISHERS	P=0.272	P=0.500	P=0.508N	P=0.339
MAX-ISO-POLY-3	P=0.335	P=0.383	P=0.269N	P=0.243

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	13/50 (26%)	15/50 (30%)	21/49 (43%)	18/50 (36%)
POLY-3 RATE (b)	13/42.03	15/44.89	21/45.00	18/45.72
POLY-3 PERCENT (g)	30.9%	33.4%	46.7%	39.4%
TERMINAL (d)	7/21 (33%)	12/33 (36%)	12/29 (41%)	11/27 (41%)
FIRST INCIDENCE	456	672	442	544

STATISTICAL TESTS

POLY 3	P=0.249	P=0.493	P=0.095	P=0.271
POLY 1.5	P=0.223	P=0.453	P=0.076	P=0.239
POLY 6	P=0.269	P=0.547	P=0.128	P=0.306
COCH-ARM / FISHERS	P=0.179	P=0.412	P=0.060	P=0.194
MAX-ISO-POLY-3	P=0.209	P=0.402	P=0.069	P=0.211

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Intermedia
 Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/39.18	0/44.49	2/42.10	0/43.06
POLY-3 PERCENT (g)	0%	0%	4.8%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	2/29 (7%)	0/27 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.702N	(e)	P=0.253	(e)
POLY 1.5	P=0.706N	(e)	P=0.244	(e)
POLY 6	P=0.701N	(e)	P=0.267	(e)
COCH-ARM / FISHERS	P=0.715	(e)	P=0.242	(e)
MAX-ISO-POLY-3	P=0.285	(e)	P=0.092	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Rathke's Cleft
 Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/39.18	0/44.49	1/42.17	0/43.06
POLY-3 PERCENT (g)	0%	0%	2.4%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	---	---	712	---

STATISTICAL TESTS

POLY 3	P=0.782N	(e)	P=0.515	(e)
POLY 1.5	P=0.784N	(e)	P=0.506	(e)
POLY 6	P=0.783N	(e)	P=0.526	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.495	(e)
MAX-ISO-POLY-3	P=0.416	(e)	P=0.177	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Preputial Gland
 Cyst**

LESION RATES

OVERALL (a)	4/50 (8%)	2/50 (4%)	0/50 (0%)	7/50 (14%)
POLY-3 RATE (b)	4/40.08	2/44.58	0/42.72	7/44.18
POLY-3 PERCENT (g)	10%	4.5%	0%	15.8%
TERMINAL (d)	1/21 (5%)	1/33 (3%)	0/29 (0%)	3/27 (11%)
FIRST INCIDENCE	589	708	---	589

STATISTICAL TESTS

POLY 3	P=0.072	P=0.289N	P=0.052N	P=0.318
POLY 1.5	P=0.072	P=0.310N	P=0.055N	P=0.296
POLY 6	P=0.070	P=0.263N	P=0.048N*	P=0.342
COCH-ARM / FISHERS	P=0.073	P=0.339N	P=0.059N	P=0.262
MAX-ISO-POLY-3	P=0.049*	P=0.176N	P=0.019N*	P=0.224

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Preputial Gland
 Inflammation Chronic**

LESION RATES

OVERALL (a)	47/50 (94%)	48/50 (96%)	41/50 (82%)	43/50 (86%)
POLY-3 RATE (b)	47/49.43	48/48.71	41/47.56	43/48.56
POLY-3 PERCENT (g)	95.1%	98.5%	86.2%	88.6%
TERMINAL (d)	19/21 (91%)	33/33 (100%)	27/29 (93%)	25/27 (93%)
FIRST INCIDENCE	387	540	387	544

STATISTICAL TESTS

POLY 3	P=0.063N	P=0.332	P=0.105N	P=0.193N
POLY 1.5	P=0.060N	P=0.358	P=0.080N	P=0.171N
POLY 6	P=0.084N	P=0.318	P=0.159N	P=0.248N
COCH-ARM / FISHERS	P=0.078N	P=0.500	P=0.061N	P=0.159N
MAX-ISO-POLY-3	P=0.045N*	P=0.147	P=0.054N	P=0.105N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Prostate
 Inflammation Chronic**

LESION RATES

OVERALL (a)	25/50 (50%)	24/50 (48%)	20/50 (40%)	20/50 (40%)
POLY-3 RATE (b)	25/44.60	24/47.06	20/44.62	20/46.45
POLY-3 PERCENT (g)	56.1%	51%	44.8%	43.1%
TERMINAL (d)	10/21 (48%)	16/33 (49%)	13/29 (45%)	8/27 (30%)
FIRST INCIDENCE	464	551	593	563

STATISTICAL TESTS

POLY 3	P=0.132N	P=0.390N	P=0.192N	P=0.146N
POLY 1.5	P=0.143N	P=0.443N	P=0.201N	P=0.169N
POLY 6	P=0.123N	P=0.324N	P=0.178N	P=0.123N
COCH-ARM / FISHERS	P=0.171N	P=0.500N	P=0.211N	P=0.211N
MAX-ISO-POLY-3	P=0.173N	P=0.316N	P=0.138N	P=0.106N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Prostate: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	9/50 (18%)	18/50 (36%)	9/50 (18%)	12/50 (24%)
POLY-3 RATE (b)	9/42.15	18/47.44	9/43.48	12/46.11
POLY-3 PERCENT (g)	21.4%	37.9%	20.7%	26%
TERMINAL (d)	0/21 (0%)	8/33 (24%)	5/29 (17%)	1/27 (4%)
FIRST INCIDENCE	547	551	631	563

STATISTICAL TESTS

POLY 3	P=0.468N	P=0.067	P=0.576N	P=0.396
POLY 1.5	P=0.498N	P=0.049*	P=0.587N	P=0.363
POLY 6	P=0.442N	P=0.098	P=0.563N	P=0.433
COCH-ARM / FISHERS	P=0.553	P=0.035*	P=0.602N	P=0.312
MAX-ISO-POLY-3	P=0.380	P=0.050*	P=0.470N	P=0.311

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skeletal Muscle
 Fibrosis**

LESION RATES

OVERALL (a)	3/8 (38%)	0/1 (0%)	2/3 (67%)	1/5 (20%)
POLY-3 RATE (b)	3/5.30	0/1.00	2/2.89	1/4.20
POLY-3 PERCENT (g)	56.6%	0%	69.2%	23.8%
TERMINAL (d)	2/2 (100%)	0/1 (0%)	2/2 (100%)	1/2 (50%)
FIRST INCIDENCE	688	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.329N	P=0.525N	P=0.664	P=0.357N
POLY 1.5	P=0.360N	P=0.581N	P=0.558	P=0.407N
POLY 6	P=0.321N	P=0.432N	P=0.792	P=0.311N
COCH-ARM / FISHERS	P=0.425N	P=0.667N	P=0.424	P=0.490N
MAX-ISO-POLY-3	P=0.254N	P=0.158N	P=0.358	P=0.146N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin
 Cyst Epithelial Inclusion**

LESION RATES

OVERALL (a)	3/50 (6%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	3/39.47	1/44.49	1/42.72	2/43.60
POLY-3 PERCENT (g)	7.6%	2.3%	2.3%	4.6%
TERMINAL (d)	2/21 (10%)	1/33 (3%)	1/29 (3%)	1/27 (4%)
FIRST INCIDENCE	651	729 (T)	729 (T)	563

STATISTICAL TESTS

POLY 3	P=0.541N	P=0.263N	P=0.277N	P=0.455N
POLY 1.5	P=0.538N	P=0.282N	P=0.289N	P=0.472N
POLY 6	P=0.549N	P=0.240N	P=0.261N	P=0.437N
COCH-ARM / FISHERS	P=0.541N	P=0.309N	P=0.309N	P=0.500N
MAX-ISO-POLY-3	P=0.265N	P=0.139N	P=0.144N	P=0.293N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin
 Fibrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	0/39.18	2/44.49	1/43.04	3/43.22
POLY-3 PERCENT (g)	0%	4.5%	2.3%	6.9%
TERMINAL (d)	0/21 (0%)	2/33 (6%)	0/29 (0%)	2/27 (7%)
FIRST INCIDENCE	---	729 (T)	641	687

STATISTICAL TESTS

POLY 3	P=0.129	P=0.266	P=0.519	P=0.137
POLY 1.5	P=0.122	P=0.253	P=0.510	P=0.130
POLY 6	P=0.134	P=0.285	P=0.530	P=0.145
COCH-ARM / FISHERS	P=0.111	P=0.247	P=0.500	P=0.121
MAX-ISO-POLY-3	P=0.086	P=0.103	P=0.181	P=0.053

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin
 Hyperkeratosis**

LESION RATES

OVERALL (a)	5/50 (10%)	3/50 (6%)	6/50 (12%)	7/50 (14%)
POLY-3 RATE (b)	5/39.64	3/44.49	6/43.09	7/43.60
POLY-3 PERCENT (g)	12.6%	6.7%	13.9%	16.1%
TERMINAL (d)	4/21 (19%)	3/33 (9%)	4/29 (14%)	5/27 (19%)
FIRST INCIDENCE	592	729 (T)	674	648

STATISTICAL TESTS

POLY 3	P=0.232	P=0.294N	P=0.559	P=0.447
POLY 1.5	P=0.228	P=0.322N	P=0.533	P=0.420
POLY 6	P=0.231	P=0.259N	P=0.596	P=0.476
COCH-ARM / FISHERS	P=0.211	P=0.357N	P=0.500	P=0.380
MAX-ISO-POLY-3	P=0.316	P=0.194N	P=0.431	P=0.334

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin: Epidermis
 Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	1/50 (2%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	3/39.64	1/44.49	3/42.88	3/43.30
POLY-3 PERCENT (g)	7.6%	2.3%	7%	6.9%
TERMINAL (d)	2/21 (10%)	1/33 (3%)	2/29 (7%)	2/27 (7%)
FIRST INCIDENCE	592	729 (T)	687	666

STATISTICAL TESTS

POLY 3	P=0.478	P=0.265N	P=0.626N	P=0.622N
POLY 1.5	P=0.477	P=0.283N	P=0.642N	P=0.637N
POLY 6	P=0.473	P=0.242N	P=0.604N	P=0.606N
COCH-ARM / FISHERS	P=0.465	P=0.309N	P=0.661N	P=0.661N
MAX-ISO-POLY-3	P=0.544N	P=0.140N	P=0.461N	P=0.456N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Fibrosis**

LESION RATES

OVERALL (a)	6/50 (12%)	1/50 (2%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	6/40.10	1/44.49	4/43.14	0/43.06
POLY-3 PERCENT (g)	15%	2.3%	9.3%	0%
TERMINAL (d)	1/21 (5%)	1/33 (3%)	2/29 (7%)	0/27 (0%)
FIRST INCIDENCE	592	729 (T)	674	---

STATISTICAL TESTS

POLY 3	P=0.026N*	P=0.040N*	P=0.323N	P=0.011N*
POLY 1.5	P=0.026N*	P=0.047N*	P=0.343N	P=0.013N*
POLY 6	P=0.028N*	P=0.033N*	P=0.297N	P=0.010N**
COCH-ARM / FISHERS	P=0.028N*	P=0.056N	P=0.370N	P=0.013N*
MAX-ISO-POLY-3	P=0.006N**	P=0.020N*	P=0.221N	P=0.004N**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	2/39.77	0/44.49	4/44.71	2/43.48
POLY-3 PERCENT (g)	5%	0%	9%	4.6%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	1/27 (4%)
FIRST INCIDENCE	604	---	442	607

STATISTICAL TESTS

POLY 3	P=0.478	P=0.213N	P=0.392	P=0.662N
POLY 1.5	P=0.475	P=0.224N	P=0.369	P=0.674N
POLY 6	P=0.473	P=0.200N	P=0.424	P=0.650N
COCH-ARM / FISHERS	P=0.462	P=0.247N	P=0.339	P=0.691N
MAX-ISO-POLY-3	P=0.295	P=0.075N	P=0.256	P=0.464N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Hemorrhage**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/39.20	0/44.49	0/42.72	0/43.06
POLY-3 PERCENT (g)	5.1%	0%	0%	0%
TERMINAL (d)	1/21 (5%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	724	---	---	---

STATISTICAL TESTS

POLY 3	P=0.187N	P=0.210N	P=0.218N	P=0.216N
POLY 1.5	P=0.179N	P=0.222N	P=0.226N	P=0.224N
POLY 6	P=0.199N	P=0.195N	P=0.207N	P=0.208N
COCH-ARM / FISHERS	P=0.171N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.033N*	P=0.075N	P=0.075N	P=0.075N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Necrosis**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/40.02	1/44.81	1/42.78	0/43.06
POLY-3 PERCENT (g)	5%	2.2%	2.3%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	547	641	712	---

STATISTICAL TESTS

POLY 3	P=0.172N	P=0.461N	P=0.477N	P=0.221N
POLY 1.5	P=0.171N	P=0.479N	P=0.487N	P=0.227N
POLY 6	P=0.176N	P=0.437N	P=0.463N	P=0.216N
COCH-ARM / FISHERS	P=0.172N	P=0.500N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.121N	P=0.259N	P=0.267N	P=0.075N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Pigmentation**

LESION RATES

OVERALL (a)	12/50 (24%)	12/50 (24%)	8/50 (16%)	12/50 (24%)
POLY-3 RATE (b)	12/42.30	12/48.23	8/44.42	12/46.14
POLY-3 PERCENT (g)	28.4%	24.9%	18%	26%
TERMINAL (d)	4/21 (19%)	4/33 (12%)	3/29 (10%)	3/27 (11%)
FIRST INCIDENCE	456	224	521	544

STATISTICAL TESTS

POLY 3	P=0.516N	P=0.446N	P=0.185N	P=0.496N
POLY 1.5	P=0.528N	P=0.506N	P=0.203N	P=0.534N
POLY 6	P=0.508N	P=0.374N	P=0.162N	P=0.453N
COCH-ARM / FISHERS	P=0.554	P=0.592N	P=0.227N	P=0.592N
MAX-ISO-POLY-3	P=0.414N	P=0.361N	P=0.130N	P=0.403N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen: Lymphoid Follicle
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	4/50 (8%)	3/50 (6%)
POLY-3 RATE (b)	0/39.18	3/44.49	4/43.29	3/43.30
POLY-3 PERCENT (g)	0%	6.7%	9.2%	6.9%
TERMINAL (d)	0/21 (0%)	3/33 (9%)	3/29 (10%)	2/27 (7%)
FIRST INCIDENCE	---	729 (T)	547	666

STATISTICAL TESTS

POLY 3	P=0.259	P=0.143	P=0.073	P=0.137
POLY 1.5	P=0.244	P=0.131	P=0.067	P=0.130
POLY 6	P=0.272	P=0.159	P=0.082	P=0.145
COCH-ARM / FISHERS	P=0.218	P=0.121	P=0.059	P=0.121
MAX-ISO-POLY-3	P=0.113	P=0.059	P=0.030*	P=0.054

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach
 Edema**

LESION RATES

OVERALL (a)	4/50 (8%)	7/50 (14%)	4/50 (8%)	4/50 (8%)
POLY-3 RATE (b)	4/40.54	7/45.71	4/43.62	4/44.30
POLY-3 PERCENT (g)	9.9%	15.3%	9.2%	9%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	547	639	641	587

STATISTICAL TESTS

POLY 3	P=0.380N	P=0.333	P=0.603N	P=0.594N
POLY 1.5	P=0.394N	P=0.299	P=0.621N	P=0.613N
POLY 6	P=0.371N	P=0.381	P=0.578N	P=0.575N
COCH-ARM / FISHERS	P=0.423N	P=0.262	P=0.643N	P=0.643N
MAX-ISO-POLY-3	P=0.483N	P=0.239	P=0.457N	P=0.449N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach
 Ulcer**

LESION RATES

OVERALL (a)	6/50 (12%)	7/50 (14%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	6/41.07	7/45.83	4/43.62	5/44.38
POLY-3 PERCENT (g)	14.6%	15.3%	9.2%	11.3%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	526	639	641	587

STATISTICAL TESTS

POLY 3	P=0.352N	P=0.584	P=0.331N	P=0.446N
POLY 1.5	P=0.360N	P=0.546	P=0.348N	P=0.465N
POLY 6	P=0.352N	P=0.603N	P=0.310N	P=0.428N
COCH-ARM / FISHERS	P=0.381N	P=0.500	P=0.370N	P=0.500N
MAX-ISO-POLY-3	P=0.428N	P=0.466	P=0.227N	P=0.329N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	5/50 (10%)	6/50 (12%)	3/50 (6%)	5/50 (10%)
POLY-3 RATE (b)	5/41.45	6/45.14	3/43.25	5/44.51
POLY-3 PERCENT (g)	12.1%	13.3%	6.9%	11.2%
TERMINAL (d)	0/21 (0%)	2/33 (6%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	547	652	659	587

STATISTICAL TESTS

POLY 3	P=0.497N	P=0.560	P=0.332N	P=0.585N
POLY 1.5	P=0.506N	P=0.533	P=0.343N	P=0.602N
POLY 6	P=0.494N	P=0.595	P=0.318N	P=0.570N
COCH-ARM / FISHERS	P=0.526N	P=0.500	P=0.357N	P=0.630N
MAX-ISO-POLY-3	P=0.487N	P=0.433	P=0.216N	P=0.453N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular
 Edema**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/39.18	0/44.49	0/42.72	1/43.27
POLY-3 PERCENT (g)	0%	0%	0%	2.3%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	---	---	---	673

STATISTICAL TESTS

POLY 3	P=0.218	(e)	(e)	P=0.520
POLY 1.5	P=0.216	(e)	(e)	P=0.512
POLY 6	P=0.218	(e)	(e)	P=0.528
COCH-ARM / FISHERS	P=0.211	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.159	(e)	(e)	P=0.182

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular
 Erosion**

LESION RATES

OVERALL (a)	6/50 (12%)	2/50 (4%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	6/40.99	2/44.96	4/43.54	5/44.34
POLY-3 PERCENT (g)	14.6%	4.5%	9.2%	11.3%
TERMINAL (d)	1/21 (5%)	0/33 (0%)	1/29 (3%)	0/27 (0%)
FIRST INCIDENCE	526	621	615	563

STATISTICAL TESTS

POLY 3	P=0.541	P=0.104N	P=0.331N	P=0.445N
POLY 1.5	P=0.540	P=0.117N	P=0.348N	P=0.465N
POLY 6	P=0.537	P=0.089N	P=0.308N	P=0.425N
COCH-ARM / FISHERS	P=0.527	P=0.134N	P=0.370N	P=0.500N
MAX-ISO-POLY-3	P=0.279N	P=0.059N	P=0.226N	P=0.328N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular
 Ulcer**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	2/39.41	1/44.56	2/43.12	1/43.26
POLY-3 PERCENT (g)	5.1%	2.2%	4.6%	2.3%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	687	712	659	676

STATISTICAL TESTS

POLY 3	P=0.447N	P=0.457N	P=0.662N	P=0.467N
POLY 1.5	P=0.448N	P=0.477N	P=0.676N	P=0.480N
POLY 6	P=0.450N	P=0.432N	P=0.641N	P=0.455N
COCH-ARM / FISHERS	P=0.456N	P=0.500N	P=0.691N	P=0.500N
MAX-ISO-POLY-3	P=0.422N	P=0.257N	P=0.464N	P=0.262N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	1/39.18	0/44.49	2/43.12	2/43.51
POLY-3 PERCENT (g)	2.6%	0%	4.6%	4.6%
TERMINAL (d)	1/21 (5%)	0/33 (0%)	1/29 (3%)	0/27 (0%)
FIRST INCIDENCE	729 (T)	---	615	666

STATISTICAL TESTS

POLY 3	P=0.286	P=0.475N	P=0.533	P=0.537
POLY 1.5	P=0.283	P=0.486N	P=0.519	P=0.522
POLY 6	P=0.285	P=0.459N	P=0.554	P=0.553
COCH-ARM / FISHERS	P=0.273	P=0.500N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.315	P=0.158N	P=0.316	P=0.320

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Testes: Germinal Epithelium
 Atrophy

LESION RATES

OVERALL (a)	9/50 (18%)	8/50 (16%)	10/50 (20%)	11/50 (22%)
POLY-3 RATE (b)	9/40.74	8/45.19	10/43.72	11/43.69
POLY-3 PERCENT (g)	22.1%	17.7%	22.9%	25.2%
TERMINAL (d)	4/21 (19%)	5/33 (15%)	5/29 (17%)	8/27 (30%)
FIRST INCIDENCE	526	641	659	666

STATISTICAL TESTS

POLY 3	P=0.322	P=0.406N	P=0.569	P=0.469
POLY 1.5	P=0.319	P=0.449N	P=0.538	P=0.445
POLY 6	P=0.312	P=0.352N	P=0.596N	P=0.489
COCH-ARM / FISHERS	P=0.298	P=0.500N	P=0.500	P=0.402
MAX-ISO-POLY-3	P=0.455	P=0.314N	P=0.466	P=0.372

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Testes: Interstitial Cell
 Hyperplasia

LESION RATES

OVERALL (a)	4/50 (8%)	2/50 (4%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	4/41.18	2/44.59	2/43.61	2/43.30
POLY-3 PERCENT (g)	9.7%	4.5%	4.6%	4.6%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	1/27 (4%)
FIRST INCIDENCE	387	705	547	666

STATISTICAL TESTS

POLY 3	P=0.331N	P=0.301N	P=0.310N	P=0.313N
POLY 1.5	P=0.330N	P=0.318N	P=0.323N	P=0.322N
POLY 6	P=0.337N	P=0.277N	P=0.292N	P=0.306N
COCH-ARM / FISHERS	P=0.332N	P=0.339N	P=0.339N	P=0.339N
MAX-ISO-POLY-3	P=0.266N	P=0.182N	P=0.186N	P=0.188N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thymus
 Atrophy**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	0/39.18	0/44.49	2/43.70	0/42.06
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/26 (0%)
FIRST INCIDENCE	---	---	442	---

STATISTICAL TESTS

POLY 3	P=0.708N	(e)	P=0.262	(e)
POLY 1.5	P=0.712N	(e)	P=0.251	(e)
POLY 6	P=0.708N	(e)	P=0.277	(e)
COCH-ARM / FISHERS	P=0.712	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.288	(e)	P=0.099	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thymus
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/39.81	0/44.49	0/42.72	0/42.06
POLY-3 PERCENT (g)	5%	0%	0%	0%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	0/29 (0%)	0/26 (0%)
FIRST INCIDENCE	589	---	---	---

STATISTICAL TESTS

POLY 3	P=0.186N	P=0.213N	P=0.221N	P=0.225N
POLY 1.5	P=0.179N	P=0.224N	P=0.228N	P=0.231N
POLY 6	P=0.196N	P=0.200N	P=0.213N	P=0.220N
COCH-ARM / FISHERS	P=0.173N	P=0.247N	P=0.247N	P=0.253N
MAX-ISO-POLY-3	P=0.033N*	P=0.075N	P=0.075N	P=0.076N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland
 Ultimobranchial Cyst**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/39.74	1/44.49	2/43.10	0/43.06
POLY-3 PERCENT (g)	2.5%	2.3%	4.6%	0%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	1/29 (3%)	0/27 (0%)
FIRST INCIDENCE	554	729 (T)	621	---

STATISTICAL TESTS

POLY 3	P=0.329N	P=0.735N	P=0.528	P=0.484N
POLY 1.5	P=0.333N	P=0.747N	P=0.516	P=0.490N
POLY 6	P=0.329N	P=0.719N	P=0.546	P=0.478N
COCH-ARM / FISHERS	P=0.343N	P=0.753N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.301N	P=0.469N	P=0.311	P=0.158N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: C-Cell
 Hyperplasia**

LESION RATES

OVERALL (a)	32/50 (64%)	33/50 (66%)	26/50 (52%)	20/50 (40%)
POLY-3 RATE (b)	32/44.11	33/46.13	26/46.10	20/45.76
POLY-3 PERCENT (g)	72.6%	71.5%	56.4%	43.7%
TERMINAL (d)	18/21 (86%)	25/33 (76%)	14/29 (48%)	11/27 (41%)
FIRST INCIDENCE	526	621	547	563

STATISTICAL TESTS

POLY 3	P<0.001N**	P=0.554N	P=0.074N	P=0.003N**
POLY 1.5	P<0.001N**	P=0.573	P=0.104N	P=0.005N**
POLY 6	P<0.001N**	P=0.480N	P=0.045N*	P=0.002N**
COCH-ARM / FISHERS	P=0.003N**	P=0.500	P=0.156N	P=0.014N*
MAX-ISO-POLY-3	P<0.001N**	P=0.455N	P=0.050N*	P=0.002N**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: Follicle
 Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	5/50 (10%)	1/50 (2%)
POLY-3 RATE (b)	0/39.18	1/45.08	5/43.05	1/43.30
POLY-3 PERCENT (g)	0%	2.2%	11.6%	2.3%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	3/29 (10%)	0/27 (0%)
FIRST INCIDENCE	---	540	659	666

STATISTICAL TESTS

POLY 3	P=0.504	P=0.528	P=0.039*	P=0.520
POLY 1.5	P=0.489	P=0.515	P=0.035*	P=0.512
POLY 6	P=0.514	P=0.544	P=0.045*	P=0.528
COCH-ARM / FISHERS	P=0.459	P=0.500	P=0.028*	P=0.500
MAX-ISO-POLY-3	P=0.103	P=0.192	P=0.016*	P=0.183

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: Follicular Cell
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/39.18	2/45.47	2/42.98	1/43.06
POLY-3 PERCENT (g)	0%	4.4%	4.7%	2.3%
TERMINAL (d)	0/21 (0%)	0/33 (0%)	1/29 (3%)	1/27 (4%)
FIRST INCIDENCE	---	540	659	729 (T)

STATISTICAL TESTS

POLY 3	P=0.589	P=0.272	P=0.258	P=0.519
POLY 1.5	P=0.575	P=0.256	P=0.249	P=0.512
POLY 6	P=0.600	P=0.294	P=0.272	P=0.526
COCH-ARM / FISHERS	P=0.548	P=0.247	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.275	P=0.108	P=0.096	P=0.181

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Tongue
 Hyperplasia

LESION RATES

OVERALL (a)	0/1 (0%)	0/0 (0%)	0/0 (0%)	2/2 (100%)
POLY-3 RATE (b)	0/1.00	0/0.00	0/0.00	2/2.00
POLY-3 PERCENT (g)	0%	0%	0%	100%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	2/2 (100%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	P=0.333
POLY 1.5	(e)	(e)	(e)	P=0.333
POLY 6	(e)	(e)	(e)	P=0.333
COCH-ARM / FISHERS	P=0.170	(e)	(e)	P=0.333
MAX-ISO-POLY-3	(e)	(e)	(e)	P<0.001**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Urinary Bladder: Transitional Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/39.18	2/44.81	0/42.72	0/43.06
POLY-3 PERCENT (g)	0%	4.5%	0%	0%
TERMINAL (d)	0/21 (0%)	1/33 (3%)	0/29 (0%)	0/27 (0%)
FIRST INCIDENCE	---	641	---	---

STATISTICAL TESTS

POLY 3	P=0.389N	P=0.268	(e)	(e)
POLY 1.5	P=0.404N	P=0.254	(e)	(e)
POLY 6	P=0.372N	P=0.289	(e)	(e)
COCH-ARM / FISHERS	P=0.425N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.278N	P=0.105	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Accessory Adrenal Cortical Nodule**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/46.64	3/46.01	1/43.15	0/44.14
POLY-3 PERCENT (g)	2.1%	6.5%	2.3%	0%
TERMINAL (d)	1/38 (3%)	3/37 (8%)	1/33 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.213N	P=0.300	P=0.743	P=0.511N
POLY 1.5	P=0.207N	P=0.301	P=0.750	P=0.507N
POLY 6	P=0.220N	P=0.300	P=0.734	P=0.516N
COCH-ARM / FISHERS	P=0.198N	P=0.309	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.176N	P=0.152	P=0.478	P=0.172N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Degeneration Fatty**

LESION RATES

OVERALL (a)	15/50 (30%)	20/50 (40%)	24/50 (48%)	13/50 (26%)
POLY-3 RATE (b)	15/48.22	20/47.39	24/46.60	13/47.54
POLY-3 PERCENT (g)	31.1%	42.2%	51.5%	27.4%
TERMINAL (d)	9/38 (24%)	14/37 (38%)	15/33 (46%)	6/37 (16%)
FIRST INCIDENCE	619	639	442	534

STATISTICAL TESTS

POLY 3	P=0.234N	P=0.180	P=0.032*	P=0.429N
POLY 1.5	P=0.230N	P=0.185	P=0.039*	P=0.423N
POLY 6	P=0.240N	P=0.178	P=0.027*	P=0.435N
COCH-ARM / FISHERS	P=0.227N	P=0.201	P=0.050*	P=0.412N
MAX-ISO-POLY-3	P=0.116N	P=0.132	P=0.022*	P=0.344N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	2/46.58	0/43.15	1/44.51
POLY-3 PERCENT (g)	0%	4.3%	0%	2.3%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	610	---	625

STATISTICAL TESTS

POLY 3	P=0.546	P=0.237	(e)	P=0.491
POLY 1.5	P=0.552	P=0.236	(e)	P=0.494
POLY 6	P=0.540	P=0.239	(e)	P=0.487
COCH-ARM / FISHERS	P=0.562	P=0.247	(e)	P=0.500
MAX-ISO-POLY-3	P=0.332	P=0.076	(e)	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	1/50 (2%)	4/50 (8%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/46.64	4/46.01	1/43.15	2/44.14
POLY-3 PERCENT (g)	2.1%	8.7%	2.3%	4.5%
TERMINAL (d)	1/38 (3%)	4/37 (11%)	1/33 (3%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.587	P=0.175	P=0.743	P=0.481
POLY 1.5	P=0.598	P=0.176	P=0.750	P=0.489
POLY 6	P=0.575	P=0.174	P=0.734	P=0.473
COCH-ARM / FISHERS	P=0.614	P=0.181	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.391	P=0.082	P=0.478	P=0.270

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Hypertrophy Focal**

LESION RATES

OVERALL (a)	12/50 (24%)	10/50 (20%)	9/50 (18%)	2/50 (4%)
POLY-3 RATE (b)	12/47.11	10/46.71	9/43.72	2/44.14
POLY-3 PERCENT (g)	25.5%	21.4%	20.6%	4.5%
TERMINAL (d)	9/38 (24%)	9/37 (24%)	8/33 (24%)	2/37 (5%)
FIRST INCIDENCE	688	485	552	729 (T)

STATISTICAL TESTS

POLY 3	P=0.005N**	P=0.413N	P=0.381N	P=0.005N**
POLY 1.5	P=0.004N**	P=0.412N	P=0.351N	P=0.004N**
POLY 6	P=0.006N**	P=0.416N	P=0.422N	P=0.006N**
COCH-ARM / FISHERS	P=0.003N**	P=0.405N	P=0.312N	P=0.004N**
MAX-ISO-POLY-3	P=0.007N**	P=0.322N	P=0.298N	P=0.003N**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Medulla
 Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	1/46.64	1/46.11	3/43.61	2/44.35
POLY-3 PERCENT (g)	2.1%	2.2%	6.9%	4.5%
TERMINAL (d)	1/38 (3%)	0/37 (0%)	2/33 (6%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	704	592	674

STATISTICAL TESTS

POLY 3	P=0.354	P=0.758	P=0.282	P=0.482
POLY 1.5	P=0.365	P=0.758	P=0.291	P=0.489
POLY 6	P=0.344	P=0.759	P=0.270	P=0.476
COCH-ARM / FISHERS	P=0.379	P=0.753N	P=0.309	P=0.500
MAX-ISO-POLY-3	P=0.319	P=0.496	P=0.146	P=0.271

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Bone Marrow
 Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	6/50 (12%)	5/50 (10%)	1/50 (2%)
POLY-3 RATE (b)	3/47.27	6/46.71	5/44.05	1/44.14
POLY-3 PERCENT (g)	6.4%	12.9%	11.4%	2.3%
TERMINAL (d)	0/38 (0%)	3/37 (8%)	3/33 (9%)	1/37 (3%)
FIRST INCIDENCE	619	652	547	729 (T)

STATISTICAL TESTS

POLY 3	P=0.170N	P=0.236	P=0.318	P=0.330N
POLY 1.5	P=0.157N	P=0.237	P=0.334	P=0.320N
POLY 6	P=0.186N	P=0.237	P=0.299	P=0.343N
COCH-ARM / FISHERS	P=0.141N	P=0.243	P=0.357	P=0.309N
MAX-ISO-POLY-3	P=0.146N	P=0.144	P=0.209	P=0.180N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Bone Marrow
 Myelofibrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Brain
 Compression**

LESION RATES

OVERALL (a)	6/50 (12%)	10/50 (20%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	6/47.30	10/46.54	4/44.04	5/44.69
POLY-3 PERCENT (g)	12.7%	21.5%	9.1%	11.2%
TERMINAL (d)	3/38 (8%)	6/37 (16%)	2/33 (6%)	4/37 (11%)
FIRST INCIDENCE	621	668	552	560

STATISTICAL TESTS

POLY 3	P=0.301N	P=0.195	P=0.415N	P=0.540N
POLY 1.5	P=0.285N	P=0.198	P=0.396N	P=0.523N
POLY 6	P=0.321N	P=0.194	P=0.439N	P=0.559N
COCH-ARM / FISHERS	P=0.265N	P=0.207	P=0.370N	P=0.500N
MAX-ISO-POLY-3	P=0.279N	P=0.130	P=0.298N	P=0.413N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Brain
 Hemorrhage**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/46.76	0/46.01	0/43.15	1/44.75
POLY-3 PERCENT (g)	2.1%	0%	0%	2.2%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	699	---	---	534

STATISTICAL TESTS

POLY 3	P=0.570	P=0.503N	P=0.516N	P=0.751
POLY 1.5	P=0.572	P=0.503N	P=0.509N	P=0.755
POLY 6	P=0.566	P=0.504N	P=0.524N	P=0.747
COCH-ARM / FISHERS	P=0.575	P=0.500N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.405	P=0.163N	P=0.178N	P=0.487

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Brain
Necrosis

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Clitoral Gland
 Cyst**

LESION RATES

OVERALL (a)	6/50 (12%)	8/50 (16%)	8/50 (16%)	4/50 (8%)
POLY-3 RATE (b)	6/46.76	8/46.71	8/44.76	4/45.21
POLY-3 PERCENT (g)	12.8%	17.1%	17.9%	8.9%
TERMINAL (d)	5/38 (13%)	4/37 (11%)	3/33 (9%)	2/37 (5%)
FIRST INCIDENCE	699	652	596	547

STATISTICAL TESTS

POLY 3	P=0.257N	P=0.386	P=0.353	P=0.391N
POLY 1.5	P=0.247N	P=0.383	P=0.366	P=0.383N
POLY 6	P=0.268N	P=0.394	P=0.342	P=0.398N
COCH-ARM / FISHERS	P=0.233N	P=0.387	P=0.387	P=0.370N
MAX-ISO-POLY-3	P=0.274N	P=0.282	P=0.257	P=0.275N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Clitoral Gland
 Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	4/50 (8%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	3/46.64	4/46.43	0/43.15	3/44.63
POLY-3 PERCENT (g)	6.4%	8.6%	0%	6.7%
TERMINAL (d)	3/38 (8%)	2/37 (5%)	0/33 (0%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	639	---	584

STATISTICAL TESTS

POLY 3	P=0.550N	P=0.498	P=0.133N	P=0.642
POLY 1.5	P=0.544N	P=0.496	P=0.127N	P=0.650
POLY 6	P=0.558N	P=0.502	P=0.141N	P=0.634
COCH-ARM / FISHERS	P=0.535N	P=0.500	P=0.121N	P=0.661N
MAX-ISO-POLY-3	P=0.323N	P=0.345	P=0.050N*	P=0.477

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Clitoral Gland
 Inflammation Chronic**

LESION RATES

OVERALL (a)	23/50 (46%)	26/50 (52%)	18/50 (36%)	24/50 (48%)
POLY-3 RATE (b)	23/47.66	26/47.07	18/44.40	24/44.78
POLY-3 PERCENT (g)	48.3%	55.2%	40.5%	53.6%
TERMINAL (d)	19/38 (50%)	22/37 (60%)	15/33 (46%)	22/37 (60%)
FIRST INCIDENCE	619	485	547	605

STATISTICAL TESTS

POLY 3	P=0.424	P=0.316	P=0.294N	P=0.379
POLY 1.5	P=0.477	P=0.325	P=0.256N	P=0.429
POLY 6	P=0.364	P=0.307	P=0.347N	P=0.323
COCH-ARM / FISHERS	P=0.545	P=0.345	P=0.208N	P=0.500
MAX-ISO-POLY-3	P=0.484	P=0.248	P=0.234N	P=0.307

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Eye
 Cataract**

LESION RATES

OVERALL (a)	3/49 (6%)	0/48 (0%)	0/47 (0%)	1/49 (2%)
POLY-3 RATE (b)	3/46.30	0/45.23	0/41.30	1/44.13
POLY-3 PERCENT (g)	6.5%	0%	0%	2.3%
TERMINAL (d)	3/38 (8%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	---	---	632

STATISTICAL TESTS

POLY 3	P=0.344N	P=0.123N	P=0.140N	P=0.323N
POLY 1.5	P=0.342N	P=0.123N	P=0.135N	P=0.316N
POLY 6	P=0.346N	P=0.122N	P=0.146N	P=0.329N
COCH-ARM / FISHERS	P=0.342N	P=0.125N	P=0.129N	P=0.309N
MAX-ISO-POLY-3	P=0.056N	P=0.040N*	P=0.055N	P=0.172N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Eye: Retina
 Degeneration

LESION RATES

OVERALL (a)	0/49 (0%)	1/48 (2%)	3/47 (6%)	0/49 (0%)
POLY-3 RATE (b)	0/46.30	1/45.23	3/41.58	0/43.78
POLY-3 PERCENT (g)	0%	2.2%	7.2%	0%
TERMINAL (d)	0/38 (0%)	1/37 (3%)	2/33 (6%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	652	---

STATISTICAL TESTS

POLY 3	P=0.580N	P=0.495	P=0.100	(e)
POLY 1.5	P=0.569N	P=0.495	P=0.104	(e)
POLY 6	P=0.592N	P=0.496	P=0.096	(e)
COCH-ARM / FISHERS	P=0.551N	P=0.495	P=0.113	(e)
MAX-ISO-POLY-3	P=0.218	P=0.157	P=0.036*	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Eye: Sclera
 Metaplasia Osseous

LESION RATES

OVERALL (a)	1/49 (2%)	0/48 (0%)	1/47 (2%)	0/49 (0%)
POLY-3 RATE (b)	1/46.30	0/45.23	1/41.30	0/43.78
POLY-3 PERCENT (g)	2.2%	0%	2.4%	0%
TERMINAL (d)	1/38 (3%)	0/37 (0%)	1/33 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.434N	P=0.505N	P=0.735	P=0.511N
POLY 1.5	P=0.430N	P=0.505N	P=0.741	P=0.507N
POLY 6	P=0.438N	P=0.504N	P=0.728	P=0.516N
COCH-ARM / FISHERS	P=0.424N	P=0.505N	P=0.742	P=0.500N
MAX-ISO-POLY-3	P=0.280N	P=0.163N	P=0.468	P=0.173N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Heart
 Cardiomyopathy**

LESION RATES

OVERALL (a)	46/50 (92%)	43/50 (86%)	43/50 (86%)	48/50 (96%)
POLY-3 RATE (b)	46/48.96	43/48.90	43/47.36	48/48.94
POLY-3 PERCENT (g)	94%	87.9%	90.8%	98.1%
TERMINAL (d)	36/38 (95%)	34/37 (92%)	32/33 (97%)	37/37 (100%)
FIRST INCIDENCE	619	337	547	510

STATISTICAL TESTS

POLY 3	P=0.108	P=0.232N	P=0.411N	P=0.274
POLY 1.5	P=0.132	P=0.238N	P=0.335N	P=0.301
POLY 6	P=0.086	P=0.250N	P=0.547N	P=0.244
COCH-ARM / FISHERS	P=0.172	P=0.262N	P=0.262N	P=0.339
MAX-ISO-POLY-3	P=0.097	P=0.134N	P=0.260N	P=0.117

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Heart
 Thrombosis**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	2/46.55	1/43.15	1/44.56
POLY-3 PERCENT (g)	0%	4.3%	2.3%	2.2%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	1/33 (3%)	0/37 (0%)
FIRST INCIDENCE	---	652	729 (T)	610

STATISTICAL TESTS

POLY 3	P=0.533	P=0.237	P=0.484	P=0.491
POLY 1.5	P=0.541	P=0.236	P=0.491	P=0.494
POLY 6	P=0.525	P=0.239	P=0.477	P=0.488
COCH-ARM / FISHERS	P=0.554	P=0.247	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.278	P=0.076	P=0.158	P=0.158

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Intestine Large, Colon
Edema

LESION RATES

OVERALL (a)	0/49 (0%)	0/46 (0%)	0/45 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/46.30	0/43.59	0/39.87	0/43.44
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

.....
STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Islets, Pancreatic
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	4/50 (8%)	1/50 (2%)	11/50 (22%)
POLY-3 RATE (b)	0/46.64	4/46.01	1/43.15	11/45.72
POLY-3 PERCENT (g)	0%	8.7%	2.3%	24.1%
TERMINAL (d)	0/38 (0%)	4/37 (11%)	1/33 (3%)	7/37 (19%)
FIRST INCIDENCE	---	729 (T)	729 (T)	510

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.059	P=0.484	P<0.001**
POLY 1.5	P<0.001**	P=0.059	P=0.491	P<0.001**
POLY 6	P<0.001**	P=0.058	P=0.477	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.059	P=0.500	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.019*	P=0.158	P<0.001**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Cyst**

LESION RATES

OVERALL (a)	2/50 (4%)	0/49 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/46.80	0/45.33	0/43.15	1/44.14
POLY-3 PERCENT (g)	4.3%	0%	0%	2.3%
TERMINAL (d)	1/38 (3%)	0/37 (0%)	0/33 (0%)	1/37 (3%)
FIRST INCIDENCE	689	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.561N	P=0.244N	P=0.256N	P=0.520N
POLY 1.5	P=0.560N	P=0.244N	P=0.248N	P=0.512N
POLY 6	P=0.563N	P=0.244N	P=0.266N	P=0.529N
COCH-ARM / FISHERS	P=0.560N	P=0.253N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.160N	P=0.082N	P=0.094N	P=0.303N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Infarct**

LESION RATES

OVERALL (a)	2/50 (4%)	0/49 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/47.42	0/45.33	1/43.47	0/44.14
POLY-3 PERCENT (g)	4.2%	0%	2.3%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	619	---	641	---

STATISTICAL TESTS

POLY 3	P=0.223N	P=0.247N	P=0.530N	P=0.254N
POLY 1.5	P=0.220N	P=0.246N	P=0.518N	P=0.247N
POLY 6	P=0.227N	P=0.249N	P=0.545N	P=0.261N
COCH-ARM / FISHERS	P=0.217N	P=0.253N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.099N	P=0.085N	P=0.314N	P=0.092N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Nephropathy**

LESION RATES

OVERALL (a)	48/50 (96%)	44/49 (90%)	43/50 (86%)	43/50 (86%)
POLY-3 RATE (b)	48/49.35	44/47.42	43/46.93	43/47.44
POLY-3 PERCENT (g)	97.3%	92.8%	91.6%	90.6%
TERMINAL (d)	37/38 (97%)	35/37 (95%)	33/33 (100%)	35/37 (95%)
FIRST INCIDENCE	619	485	547	534

STATISTICAL TESTS

POLY 3	P=0.147N	P=0.276N	P=0.183N	P=0.140N
POLY 1.5	P=0.112N	P=0.250N	P=0.118N	P=0.102N
POLY 6	P=0.238N	P=0.317N	P=0.355N	P=0.241N
COCH-ARM / FISHERS	P=0.100N	P=0.210N	P=0.080N	P=0.080N
MAX-ISO-POLY-3	P=0.117N	P=0.138N	P=0.081N	P=0.062N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	3/50 (6%)	0/49 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	3/47.03	0/45.33	0/43.15	2/44.30
POLY-3 PERCENT (g)	6.4%	0%	0%	4.5%
TERMINAL (d)	2/38 (5%)	0/37 (0%)	0/33 (0%)	1/37 (3%)
FIRST INCIDENCE	619	---	---	688

STATISTICAL TESTS

POLY 3	P=0.637	P=0.125N	P=0.135N	P=0.527N
POLY 1.5	P=0.641N	P=0.125N	P=0.128N	P=0.516N
POLY 6	P=0.631	P=0.125N	P=0.144N	P=0.539N
COCH-ARM / FISHERS	P=0.639N	P=0.125N	P=0.121N	P=0.500N
MAX-ISO-POLY-3	P=0.131N	P=0.043N*	P=0.052N	P=0.352N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Necrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	0/45.33	0/43.15	1/44.75
POLY-3 PERCENT (g)	0%	0%	0%	2.2%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	534

STATISTICAL TESTS

POLY 3	P=0.207	(e)	(e)	P=0.492
POLY 1.5	P=0.209	(e)	(e)	P=0.495
POLY 6	P=0.204	(e)	(e)	P=0.488
COCH-ARM / FISHERS	P=0.212	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.125	(e)	(e)	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Pigmentation**

LESION RATES

OVERALL (a)	1/50 (2%)	0/49 (0%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	1/47.03	0/45.33	2/44.11	3/45.12
POLY-3 PERCENT (g)	2.1%	0%	4.5%	6.7%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	619	---	575	610

STATISTICAL TESTS

POLY 3	P=0.106	P=0.507N	P=0.478	P=0.291
POLY 1.5	P=0.109	P=0.507N	P=0.487	P=0.296
POLY 6	P=0.103	P=0.508N	P=0.467	P=0.286
COCH-ARM / FISHERS	P=0.113	P=0.505N	P=0.500	P=0.309
MAX-ISO-POLY-3	P=0.111	P=0.167N	P=0.268	P=0.148

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Basophilic Focus

LESION RATES

OVERALL (a)	47/50 (94%)	46/50 (92%)	42/50 (84%)	38/50 (76%)
POLY-3 RATE (b)	47/49.51	46/48.98	42/46.65	38/44.69
POLY-3 PERCENT (g)	94.9%	93.9%	90%	85%
TERMINAL (d)	37/38 (97%)	37/37 (100%)	33/33 (100%)	37/37 (100%)
FIRST INCIDENCE	512	337	547	560

STATISTICAL TESTS

POLY 3	P=0.027N*	P=0.595N	P=0.272N	P=0.064N
POLY 1.5	P=0.009N**	P=0.546N	P=0.174N	P=0.027N*
POLY 6	P=0.130N	P=0.695N	P=0.486N	P=0.240N
COCH-ARM / FISHERS	P=0.003N**	P=0.500N	P=0.100N	P=0.011N*
MAX-ISO-POLY-3	P=0.041N*	P=0.403N	P=0.152N	P=0.032N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Clear Cell Focus

LESION RATES

OVERALL (a)	14/50 (28%)	10/50 (20%)	11/50 (22%)	14/50 (28%)
POLY-3 RATE (b)	14/46.64	10/46.42	11/43.15	14/44.14
POLY-3 PERCENT (g)	30%	21.5%	25.5%	31.7%
TERMINAL (d)	14/38 (37%)	9/37 (24%)	11/33 (33%)	14/37 (38%)
FIRST INCIDENCE	729 (T)	610	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.347	P=0.242N	P=0.404N	P=0.521
POLY 1.5	P=0.376	P=0.246N	P=0.369N	P=0.548
POLY 6	P=0.315	P=0.235N	P=0.449N	P=0.492
COCH-ARM / FISHERS	P=0.413	P=0.241N	P=0.322N	P=0.588N
MAX-ISO-POLY-3	P=0.425	P=0.176N	P=0.322N	P=0.430

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Degeneration Cystic

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	1/44.14
POLY-3 PERCENT (g)	0%	0%	0%	2.3%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	1/37 (3%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.204	(e)	(e)	P=0.489
POLY 1.5	P=0.207	(e)	(e)	P=0.493
POLY 6	P=0.201	(e)	(e)	P=0.484
COCH-ARM / FISHERS	P=0.211	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.124	(e)	(e)	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Eosinophilic Focus

LESION RATES

OVERALL (a)	5/50 (10%)	0/50 (0%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	5/47.03	0/46.01	4/44.05	0/44.14
POLY-3 PERCENT (g)	10.6%	0%	9.1%	0%
TERMINAL (d)	4/38 (11%)	0/37 (0%)	1/33 (3%)	0/37 (0%)
FIRST INCIDENCE	619	---	552	---

STATISTICAL TESTS

POLY 3	P=0.064N	P=0.032N*	P=0.541N	P=0.036N*
POLY 1.5	P=0.061N	P=0.032N*	P=0.524N	P=0.034N*
POLY 6	P=0.068N	P=0.033N*	P=0.561N	P=0.039N*
COCH-ARM / FISHERS	P=0.061N	P=0.028N*	P=0.500N	P=0.028N*
MAX-ISO-POLY-3	P=0.016N*	P=0.011N*	P=0.404N	P=0.014N*

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
Hepatodiaphragmatic Nodule

LESION RATES

OVERALL (a)	10/50 (20%)	9/50 (18%)	11/50 (22%)	9/50 (18%)
POLY-3 RATE (b)	10/48.18	9/46.72	11/45.22	9/44.91
POLY-3 PERCENT (g)	20.8%	19.3%	24.3%	20%
TERMINAL (d)	6/38 (16%)	5/37 (14%)	6/33 (18%)	7/37 (19%)
FIRST INCIDENCE	512	659	547	534

.....
STATISTICAL TESTS

POLY 3	P=0.549N	P=0.530N	P=0.435	P=0.568N
POLY 1.5	P=0.520N	P=0.521N	P=0.460	P=0.540N
POLY 6	P=0.528	P=0.535N	P=0.407	P=0.598N
COCH-ARM / FISHERS	P=0.481N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.626	P=0.428N	P=0.344	P=0.466N

.....

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Infiltration Cellular Mixed Cell

LESION RATES

OVERALL (a)	21/50 (42%)	33/50 (66%)	32/50 (64%)	31/50 (62%)
POLY-3 RATE (b)	21/47.65	33/47.00	32/44.59	31/44.14
POLY-3 PERCENT (g)	44.1%	70.2%	71.8%	70.2%
TERMINAL (d)	17/38 (45%)	30/37 (81%)	28/33 (85%)	31/37 (84%)
FIRST INCIDENCE	619	485	547	729 (T)

STATISTICAL TESTS

POLY 3	P=0.020*	P=0.007**	P=0.004**	P=0.007**
POLY 1.5	P=0.044*	P=0.008**	P=0.009**	P=0.015*
POLY 6	P=0.006**	P=0.005**	P=0.002**	P=0.003**
COCH-ARM / FISHERS	P=0.103	P=0.013*	P=0.022*	P=0.036*
MAX-ISO-POLY-3	P=0.005**	P=0.004**	P=0.003**	P=0.005**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Mixed Cell Focus

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/46.80	0/46.01	2/43.15	0/44.14
POLY-3 PERCENT (g)	2.1%	0%	4.6%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	2/33 (6%)	0/37 (0%)
FIRST INCIDENCE	688	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.454N	P=0.503N	P=0.472	P=0.512N
POLY 1.5	P=0.447N	P=0.503N	P=0.484	P=0.507N
POLY 6	P=0.462N	P=0.504N	P=0.457	P=0.517N
COCH-ARM / FISHERS	P=0.438N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.342N	P=0.163N	P=0.265	P=0.173N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Necrosis Focal

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	0/46.01	1/43.15	1/44.14
POLY-3 PERCENT (g)	0%	0%	2.3%	2.3%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	1/33 (3%)	1/37 (3%)
FIRST INCIDENCE	---	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.270	(e)	P=0.484	P=0.489
POLY 1.5	P=0.276	(e)	P=0.491	P=0.493
POLY 6	P=0.263	(e)	P=0.477	P=0.484
COCH-ARM / FISHERS	P=0.284	(e)	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.251	(e)	P=0.158	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Bile Duct
 Hyperplasia

LESION RATES

OVERALL (a)	12/50 (24%)	16/50 (32%)	18/50 (36%)	24/50 (48%)
POLY-3 RATE (b)	12/47.68	16/46.40	18/44.23	24/45.28
POLY-3 PERCENT (g)	25.2%	34.5%	40.7%	53%
TERMINAL (d)	8/38 (21%)	13/37 (35%)	13/33 (39%)	20/37 (54%)
FIRST INCIDENCE	619	652	592	610

STATISTICAL TESTS

POLY 3	P=0.003**	P=0.223	P=0.084	P=0.004**
POLY 1.5	P=0.004**	P=0.232	P=0.104	P=0.006**
POLY 6	P=0.002**	P=0.213	P=0.064	P=0.003**
COCH-ARM / FISHERS	P=0.008**	P=0.252	P=0.138	P=0.011*
MAX-ISO-POLY-3	P=0.004**	P=0.165	P=0.060	P=0.002**

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Hepatocyte
Hyperplasia

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

.....
STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Hepatocyte
 Vacuolization Cytoplasmic

LESION RATES

OVERALL (a)	6/50 (12%)	4/50 (8%)	7/50 (14%)	5/50 (10%)
POLY-3 RATE (b)	6/47.80	4/46.90	7/45.11	5/45.97
POLY-3 PERCENT (g)	12.6%	8.5%	15.5%	10.9%
TERMINAL (d)	3/38 (8%)	1/37 (3%)	2/33 (6%)	1/37 (3%)
FIRST INCIDENCE	619	639	547	547

STATISTICAL TESTS

POLY 3	P=0.550N	P=0.382N	P=0.455	P=0.527N
POLY 1.5	P=0.539N	P=0.379N	P=0.473	P=0.517N
POLY 6	P=0.561N	P=0.382N	P=0.435	P=0.537N
COCH-ARM / FISHERS	P=0.524N	P=0.370N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.553	P=0.266N	P=0.345	P=0.401N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver: Kupffer Cell
 Pigmentation**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/46.64	0/46.01	0/43.15	0/44.14
POLY-3 PERCENT (g)	4.3%	0%	0%	0%
TERMINAL (d)	2/38 (5%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.168N	P=0.240N	P=0.255N	P=0.250N
POLY 1.5	P=0.168N	P=0.240N	P=0.248N	P=0.245N
POLY 6	P=0.169N	P=0.240N	P=0.264N	P=0.255N
COCH-ARM / FISHERS	P=0.171N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.043N*	P=0.079N	P=0.093N	P=0.088N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	31/50 (62%)	37/50 (74%)	26/50 (52%)	27/50 (54%)
POLY-3 RATE (b)	31/48.23	37/47.86	26/44.40	27/44.14
POLY-3 PERCENT (g)	64.3%	77.3%	58.6%	61.2%
TERMINAL (d)	25/38 (66%)	31/37 (84%)	23/33 (70%)	27/37 (73%)
FIRST INCIDENCE	619	485	547	729 (T)

STATISTICAL TESTS

POLY 3	P=0.225N	P=0.113	P=0.360N	P=0.462N
POLY 1.5	P=0.157N	P=0.120	P=0.288N	P=0.373N
POLY 6	P=0.345N	P=0.106	P=0.466N	P=0.586N
COCH-ARM / FISHERS	P=0.101N	P=0.142	P=0.210N	P=0.272N
MAX-ISO-POLY-3	P=0.218N	P=0.075	P=0.290N	P=0.379N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Inflammation Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/46.64	1/46.01	1/43.54	1/44.14
POLY-3 PERCENT (g)	2.1%	2.2%	2.3%	2.3%
TERMINAL (d)	1/38 (3%)	1/37 (3%)	0/33 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	619	729 (T)

STATISTICAL TESTS

POLY 3	P=0.638	P=0.757	P=0.745	P=0.748
POLY 1.5	P=0.646	P=0.758	P=0.751	P=0.753
POLY 6	P=0.630	P=0.758	P=0.738	P=0.743
COCH-ARM / FISHERS	P=0.657	P=0.753N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.729	P=0.495	P=0.480	P=0.484

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung: Alveolar Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	12/50 (24%)	13/50 (26%)	11/50 (22%)	10/50 (20%)
POLY-3 RATE (b)	12/47.38	13/47.19	11/43.47	10/44.14
POLY-3 PERCENT (g)	25.3%	27.6%	25.3%	22.7%
TERMINAL (d)	8/38 (21%)	11/37 (30%)	9/33 (27%)	10/37 (27%)
FIRST INCIDENCE	619	337	687	729 (T)

STATISTICAL TESTS

POLY 3	P=0.389N	P=0.495	P=0.594N	P=0.478N
POLY 1.5	P=0.355N	P=0.498	P=0.555N	P=0.447N
POLY 6	P=0.431N	P=0.490	P=0.549	P=0.516N
COCH-ARM / FISHERS	P=0.311N	P=0.500	P=0.500N	P=0.405N
MAX-ISO-POLY-3	P=0.544N	P=0.402	P=0.498N	P=0.385N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Ectasia**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	3/49 (6%)	4/50 (8%)
POLY-3 RATE (b)	2/46.64	0/46.01	3/42.66	4/44.14
POLY-3 PERCENT (g)	4.3%	0%	7%	9.1%
TERMINAL (d)	2/38 (5%)	0/37 (0%)	3/33 (9%)	4/37 (11%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.106	P=0.240N	P=0.459	P=0.312
POLY 1.5	P=0.111	P=0.240N	P=0.472	P=0.322
POLY 6	P=0.100	P=0.240N	P=0.444	P=0.301
COCH-ARM / FISHERS	P=0.119	P=0.247N	P=0.490	P=0.339
MAX-ISO-POLY-3	P=0.110	P=0.079N	P=0.296	P=0.188

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node, Mesenteric Hemorrhage

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	1/42.66	0/44.14
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	1/33 (3%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.772	(e)	P=0.482	(e)
POLY 1.5	P=0.779	(e)	P=0.488	(e)
POLY 6	P=0.765	(e)	P=0.475	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.495	(e)
MAX-ISO-POLY-3	P=0.382	(e)	P=0.157	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Hyperplasia**

LESION RATES

OVERALL (a)	29/50 (58%)	34/50 (68%)	24/49 (49%)	19/50 (38%)
POLY-3 RATE (b)	29/48.39	34/47.99	24/43.88	19/45.63
POLY-3 PERCENT (g)	59.9%	70.9%	54.7%	41.6%
TERMINAL (d)	22/38 (58%)	28/37 (76%)	20/33 (61%)	16/37 (43%)
FIRST INCIDENCE	619	485	547	510

STATISTICAL TESTS

POLY 3	P=0.009N**	P=0.177	P=0.381N	P=0.054N
POLY 1.5	P=0.007N**	P=0.184	P=0.317N	P=0.044N*
POLY 6	P=0.014N*	P=0.169	P=0.474N	P=0.071N
COCH-ARM / FISHERS	P=0.006N**	P=0.204	P=0.243N	P=0.036N*
MAX-ISO-POLY-3	P=0.014N*	P=0.128	P=0.310N	P=0.039N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/49 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	1/46.29	1/43.24	1/44.14
POLY-3 PERCENT (g)	0%	2.2%	2.3%	2.3%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	1/37 (3%)
FIRST INCIDENCE	---	652	547	729 (T)

STATISTICAL TESTS

POLY 3	P=0.417	P=0.498	P=0.485	P=0.489
POLY 1.5	P=0.426	P=0.498	P=0.489	P=0.493
POLY 6	P=0.408	P=0.500	P=0.480	P=0.484
COCH-ARM / FISHERS	P=0.438	P=0.500	P=0.495	P=0.500
MAX-ISO-POLY-3	P=0.332	P=0.159	P=0.157	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Pigmentation**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/46.64	0/46.01	2/42.66	0/44.14
POLY-3 PERCENT (g)	2.1%	0%	4.7%	0%
TERMINAL (d)	1/38 (3%)	0/37 (0%)	2/33 (6%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.454N	P=0.503N	P=0.469	P=0.511N
POLY 1.5	P=0.447N	P=0.502N	P=0.479	P=0.507N
POLY 6	P=0.461N	P=0.503N	P=0.457	P=0.516N
COCH-ARM / FISHERS	P=0.438N	P=0.500N	P=0.492	P=0.500N
MAX-ISO-POLY-3	P=0.341N	P=0.162N	P=0.262	P=0.172N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node: Mediastinal
 Ectasia**

LESION RATES

OVERALL (a)	0/5 (0%)	2/10 (20%)	1/16 (6%)	0/10 (0%)
POLY-3 RATE (b)	0/4.37	2/8.54	1/12.40	0/6.61
POLY-3 PERCENT (g)	0%	23.4%	8.1%	0%
TERMINAL (d)	0/2 (0%)	2/5 (40%)	1/6 (17%)	0/2 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.395N	P=0.389	P=0.712	(e)
POLY 1.5	P=0.365N	P=0.391	P=0.718	(e)
POLY 6	P=0.440N	P=0.391	P=0.704	(e)
COCH-ARM / FISHERS	P=0.331N	P=0.429	P=0.762	(e)
MAX-ISO-POLY-3	P=0.329N	P=0.173	P=0.306	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node: Mediastinal Hemorrhage

LESION RATES

OVERALL (a)	0/5 (0%)	3/10 (30%)	1/16 (6%)	1/10 (10%)
POLY-3 RATE (b)	0/4.37	3/8.83	1/12.72	1/6.61
POLY-3 PERCENT (g)	0%	34%	7.9%	15.1%
TERMINAL (d)	0/2 (0%)	2/5 (40%)	0/6 (0%)	1/2 (50%)
FIRST INCIDENCE	---	652	641	729 (T)

STATISTICAL TESTS

POLY 3	P=0.609N	P=0.244	P=0.715	P=0.586
POLY 1.5	P=0.574N	P=0.243	P=0.720	P=0.610
POLY 6	P=0.630	P=0.253	P=0.712	P=0.546
COCH-ARM / FISHERS	P=0.532N	P=0.264	P=0.762	P=0.667
MAX-ISO-POLY-3	P=0.355	P=0.113	P=0.310	P=0.206

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node: Mediastinal
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	2/5 (40%)	2/10 (20%)	3/16 (19%)	0/10 (0%)
POLY-3 RATE (b)	2/4.61	2/9.51	3/12.72	0/6.61
POLY-3 PERCENT (g)	43.4%	21%	23.6%	0%
TERMINAL (d)	0/2 (0%)	0/5 (0%)	2/6 (33%)	0/2 (0%)
FIRST INCIDENCE	689	485	641	---

STATISTICAL TESTS

POLY 3	P=0.109N	P=0.408N	P=0.417N	P=0.111N
POLY 1.5	P=0.085N	P=0.414N	P=0.391N	P=0.086N
POLY 6	P=0.152N	P=0.401N	P=0.457N	P=0.164N
COCH-ARM / FISHERS	P=0.064N	P=0.407N	P=0.338N	P=0.095N
MAX-ISO-POLY-3	P=0.065N	P=0.237N	P=0.244N	P=0.017N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node: Pancreatic
 Ectasia

LESION RATES

OVERALL (a)	0/5 (0%)	0/10 (0%)	1/16 (6%)	0/10 (0%)
POLY-3 RATE (b)	0/4.37	0/8.54	1/12.40	0/6.61
POLY-3 PERCENT (g)	0%	0%	8.1%	0%
TERMINAL (d)	0/2 (0%)	0/5 (0%)	1/6 (17%)	0/2 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.773	(e)	P=0.712	(e)
POLY 1.5	P=0.785N	(e)	P=0.718	(e)
POLY 6	P=0.706	(e)	P=0.704	(e)
COCH-ARM / FISHERS	P=0.774N	(e)	P=0.762	(e)
MAX-ISO-POLY-3	P=0.514	(e)	P=0.306	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node: Pancreatic Hemorrhage

LESION RATES

OVERALL (a)	1/5 (20%)	2/10 (20%)	3/16 (19%)	2/10 (20%)
POLY-3 RATE (b)	1/4.46	2/8.74	3/12.40	2/6.95
POLY-3 PERCENT (g)	22.4%	22.9%	24.2%	28.8%
TERMINAL (d)	0/2 (0%)	1/5 (20%)	3/6 (50%)	1/2 (50%)
FIRST INCIDENCE	708	679	729 (T)	632

STATISTICAL TESTS

POLY 3	P=0.517	P=0.738	P=0.718	P=0.673
POLY 1.5	P=0.569	P=0.737	P=0.733	P=0.705
POLY 6	P=0.436	P=0.745	P=0.697	P=0.620
COCH-ARM / FISHERS	P=0.632	P=0.736N	P=0.696N	P=0.736N
MAX-ISO-POLY-3	P=0.637	P=0.493	P=0.474	P=0.410

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node: Pancreatic
 Hyperplasia**

LESION RATES

OVERALL (a)	0/5 (0%)	0/10 (0%)	1/16 (6%)	0/10 (0%)
POLY-3 RATE (b)	0/4.37	0/8.54	1/12.40	0/6.61
POLY-3 PERCENT (g)	0%	0%	8.1%	0%
TERMINAL (d)	0/2 (0%)	0/5 (0%)	1/6 (17%)	0/2 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.773	(e)	P=0.712	(e)
POLY 1.5	P=0.785N	(e)	P=0.718	(e)
POLY 6	P=0.706	(e)	P=0.704	(e)
COCH-ARM / FISHERS	P=0.774N	(e)	P=0.762	(e)
MAX-ISO-POLY-3	P=0.514	(e)	P=0.306	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mammary Gland
 Cyst**

LESION RATES

OVERALL (a)	15/50 (30%)	3/50 (6%)	9/50 (18%)	3/50 (6%)
POLY-3 RATE (b)	15/47.12	3/46.24	9/43.87	3/44.69
POLY-3 PERCENT (g)	31.8%	6.5%	20.5%	6.7%
TERMINAL (d)	13/38 (34%)	2/37 (5%)	7/33 (21%)	2/37 (5%)
FIRST INCIDENCE	619	668	552	560

STATISTICAL TESTS

POLY 3	P=0.008N**	P<0.001N**	P=0.160N	P=0.002N**
POLY 1.5	P=0.008N**	P<0.001N**	P=0.143N	P=0.002N**
POLY 6	P=0.009N**	P<0.001N**	P=0.184N	P=0.002N**
COCH-ARM / FISHERS	P=0.009N**	P=0.002N**	P=0.121N	P=0.002N**
MAX-ISO-POLY-3	P<0.001N**	P<0.001N**	P=0.117N	P<0.001N**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mammary Gland
 Hyperplasia**

LESION RATES

OVERALL (a)	48/50 (96%)	40/50 (80%)	35/50 (70%)	23/50 (46%)
POLY-3 RATE (b)	48/48.96	40/48.24	35/47.94	23/48.93
POLY-3 PERCENT (g)	98%	82.9%	73%	47%
TERMINAL (d)	38/38 (100%)	30/37 (81%)	22/33 (67%)	12/37 (32%)
FIRST INCIDENCE	619	610	547	520

STATISTICAL TESTS

POLY 3	P<0.001N**	P=0.009N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.011N*	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P=0.007N**	P<0.001N**	P<0.001N**
COCH-ARM / FISHERS	P<0.001N**	P=0.014N*	P<0.001N**	P<0.001N**
MAX-ISO-POLY-3	P<0.001N**	P=0.003N**	P<0.001N**	P<0.001N**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Mesentery
 Accessory Spleen

LESION RATES

OVERALL (a)	2/13 (15%)	0/14 (0%)	3/15 (20%)	2/15 (13%)
POLY-3 RATE (b)	2/11.42	0/12.82	3/12.43	2/12.22
POLY-3 PERCENT (g)	17.5%	0%	24.1%	16.4%
TERMINAL (d)	2/9 (22%)	0/9 (0%)	2/9 (22%)	2/9 (22%)
FIRST INCIDENCE	729 (T)	---	619	729 (T)

STATISTICAL TESTS

POLY 3	P=0.456	P=0.202N	P=0.541	P=0.678N
POLY 1.5	P=0.478	P=0.206N	P=0.553	P=0.664N
POLY 6	P=0.433	P=0.199N	P=0.528	P=0.695N
COCH-ARM / FISHERS	P=0.510	P=0.222N	P=0.572	P=0.644N
MAX-ISO-POLY-3	P=0.329	P=0.064N	P=0.348	P=0.470N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Mesentery: Fat
 Necrosis

LESION RATES

OVERALL (a)	12/13 (92%)	14/14 (100%)	14/15 (93%)	12/15 (80%)
POLY-3 RATE (b)	12/13.00	14/14.00	14/15.00	12/14.84
POLY-3 PERCENT (g)	92.3%	100%	93.3%	80.9%
TERMINAL (d)	8/9 (89%)	9/9 (100%)	8/9 (89%)	7/9 (78%)
FIRST INCIDENCE	512	610	547	510

STATISTICAL TESTS

POLY 3	P=0.118N	P=0.485	P=0.728	P=0.374N
POLY 1.5	P=0.111N	P=0.485	P=0.728	P=0.363N
POLY 6	P=0.133N	P=0.485	P=0.728	P=0.394N
COCH-ARM / FISHERS	P=0.103N	P=0.481	P=0.722	P=0.356N
MAX-ISO-POLY-3	P=0.122N	P=0.154	P=0.460	P=0.200N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Nose
 Foreign Body

LESION RATES

OVERALL (a)	6/50 (12%)	4/50 (8%)	6/50 (12%)	3/50 (6%)
POLY-3 RATE (b)	6/46.64	4/46.71	6/43.54	3/44.14
POLY-3 PERCENT (g)	12.9%	8.6%	13.8%	6.8%
TERMINAL (d)	6/38 (16%)	2/37 (5%)	5/33 (15%)	3/37 (8%)
FIRST INCIDENCE	729 (T)	610	619	729 (T)

STATISTICAL TESTS

POLY 3	P=0.272N	P=0.369N	P=0.572	P=0.270N
POLY 1.5	P=0.258N	P=0.372N	P=0.592	P=0.259N
POLY 6	P=0.289N	P=0.361N	P=0.548	P=0.281N
COCH-ARM / FISHERS	P=0.239N	P=0.370N	P=0.620N	P=0.243N
MAX-ISO-POLY-3	P=0.290N	P=0.253N	P=0.449	P=0.174N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Nose
 Inflammation**

LESION RATES

OVERALL (a)	3/50 (6%)	2/50 (4%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	3/46.64	2/46.01	3/43.47	0/44.14
POLY-3 PERCENT (g)	6.4%	4.4%	6.9%	0%
TERMINAL (d)	3/38 (8%)	2/37 (5%)	2/33 (6%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	641	---

STATISTICAL TESTS

POLY 3	P=0.116N	P=0.506N	P=0.629	P=0.129N
POLY 1.5	P=0.112N	P=0.505N	P=0.643	P=0.125N
POLY 6	P=0.122N	P=0.506N	P=0.614	P=0.133N
COCH-ARM / FISHERS	P=0.105N	P=0.500N	P=0.661N	P=0.121N
MAX-ISO-POLY-3	P=0.115N	P=0.330N	P=0.465	P=0.046N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Nose
 Inflammation Chronic**

LESION RATES

OVERALL (a)	3/50 (6%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	3/46.64	2/46.71	1/43.15	0/44.14
POLY-3 PERCENT (g)	6.4%	4.3%	2.3%	0%
TERMINAL (d)	3/38 (8%)	0/37 (0%)	1/33 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	610	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.081N	P=0.499N	P=0.334N	P=0.129N
POLY 1.5	P=0.078N	P=0.501N	P=0.322N	P=0.125N
POLY 6	P=0.084N	P=0.494N	P=0.348N	P=0.133N
COCH-ARM / FISHERS	P=0.075N	P=0.500N	P=0.309N	P=0.121N
MAX-ISO-POLY-3	P=0.075N	P=0.323N	P=0.183N	P=0.046N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Nose: Respiratory Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	7/50 (14%)	8/50 (16%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	7/46.64	8/46.71	1/43.15	1/44.14
POLY-3 PERCENT (g)	15%	17.1%	2.3%	2.3%
TERMINAL (d)	7/38 (18%)	6/37 (16%)	1/33 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	610	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.009N**	P=0.501	P=0.039N*	P=0.036N*
POLY 1.5	P=0.009N**	P=0.497	P=0.035N*	P=0.034N*
POLY 6	P=0.010N**	P=0.510	P=0.044N*	P=0.039N*
COCH-ARM / FISHERS	P=0.009N**	P=0.500	P=0.030N*	P=0.030N*
MAX-ISO-POLY-3	P=0.014N*	P=0.389	P=0.020N*	P=0.017N*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Ovary
 Cyst**

LESION RATES

OVERALL (a)	3/50 (6%)	5/50 (10%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/47.03	5/46.48	2/44.29	1/44.69
POLY-3 PERCENT (g)	6.4%	10.8%	4.5%	2.2%
TERMINAL (d)	2/38 (5%)	3/37 (8%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	619	652	547	560

STATISTICAL TESTS

POLY 3	P=0.155N	P=0.350	P=0.527N	P=0.324N
POLY 1.5	P=0.149N	P=0.351	P=0.516N	P=0.316N
POLY 6	P=0.162N	P=0.352	P=0.541N	P=0.332N
COCH-ARM / FISHERS	P=0.141N	P=0.357	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.171N	P=0.228	P=0.352N	P=0.173N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Ovary: Bursa
 Dilatation**

LESION RATES

OVERALL (a)	6/50 (12%)	6/50 (12%)	2/50 (4%)	6/50 (12%)
POLY-3 RATE (b)	6/46.76	6/46.01	2/43.60	6/44.72
POLY-3 PERCENT (g)	12.8%	13%	4.6%	13.4%
TERMINAL (d)	5/38 (13%)	6/37 (16%)	1/33 (3%)	4/37 (11%)
FIRST INCIDENCE	699	729 (T)	596	625

STATISTICAL TESTS

POLY 3	P=0.550	P=0.609	P=0.156N	P=0.589
POLY 1.5	P=0.560	P=0.611	P=0.147N	P=0.601
POLY 6	P=0.540	P=0.608	P=0.169N	P=0.579
COCH-ARM / FISHERS	P=0.575	P=0.620N	P=0.134N	P=0.620N
MAX-ISO-POLY-3	P=0.450N	P=0.487	P=0.091N	P=0.467

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas
 Atrophy**

LESION RATES

OVERALL (a)	10/50 (20%)	10/50 (20%)	16/50 (32%)	26/50 (52%)
POLY-3 RATE (b)	10/47.41	10/46.84	16/44.94	26/47.30
POLY-3 PERCENT (g)	21.1%	21.4%	35.6%	55%
TERMINAL (d)	6/38 (16%)	6/37 (16%)	11/33 (33%)	19/37 (51%)
FIRST INCIDENCE	619	610	552	510

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.587	P=0.092	P<0.001**
POLY 1.5	P<0.001**	P=0.588	P=0.105	P<0.001**
POLY 6	P<0.001**	P=0.589	P=0.078	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.598N	P=0.127	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.487	P=0.063	P<0.001**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas
 Cyst**

LESION RATES

OVERALL (a)	3/50 (6%)	7/50 (14%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	3/47.03	7/46.71	4/43.61	2/44.14
POLY-3 PERCENT (g)	6.4%	15%	9.2%	4.5%
TERMINAL (d)	2/38 (5%)	5/37 (14%)	3/33 (9%)	2/37 (5%)
FIRST INCIDENCE	619	610	592	729 (T)

STATISTICAL TESTS

POLY 3	P=0.256N	P=0.155	P=0.459	P=0.529N
POLY 1.5	P=0.241N	P=0.155	P=0.476	P=0.517N
POLY 6	P=0.274N	P=0.156	P=0.439	P=0.542N
COCH-ARM / FISHERS	P=0.222N	P=0.159	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.254N	P=0.089	P=0.317	P=0.354N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas
 Infiltration Cellular Lymphocyte**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	0/46.64	0/46.01	1/43.15	3/44.14
POLY-3 PERCENT (g)	0%	0%	2.3%	6.8%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	1/33 (3%)	3/37 (8%)
FIRST INCIDENCE	---	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.019*	(e)	P=0.484	P=0.109
POLY 1.5	P=0.020*	(e)	P=0.491	P=0.113
POLY 6	P=0.018*	(e)	P=0.477	P=0.105
COCH-ARM / FISHERS	P=0.021*	(e)	P=0.500	P=0.121
MAX-ISO-POLY-3	P=0.023*	(e)	P=0.158	P=0.038*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas: Acinus
 Cytoplasmic Alteration**

LESION RATES

OVERALL (a)	0/50 (0%)	4/50 (8%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/46.64	4/46.90	1/43.15	2/45.38
POLY-3 PERCENT (g)	0%	8.5%	2.3%	4.4%
TERMINAL (d)	0/38 (0%)	1/37 (3%)	1/33 (3%)	0/37 (0%)
FIRST INCIDENCE	---	639	729 (T)	510

STATISTICAL TESTS

POLY 3	P=0.444	P=0.061	P=0.484	P=0.231
POLY 1.5	P=0.450	P=0.060	P=0.491	P=0.234
POLY 6	P=0.439	P=0.063	P=0.477	P=0.229
COCH-ARM / FISHERS	P=0.459	P=0.059	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.158	P=0.020*	P=0.158	P=0.076

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas: Acinus
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	0/46.64	0/46.01	1/43.15	3/44.14
POLY-3 PERCENT (g)	0%	0%	2.3%	6.8%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	1/33 (3%)	3/37 (8%)
FIRST INCIDENCE	---	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.019*	(e)	P=0.484	P=0.109
POLY 1.5	P=0.020*	(e)	P=0.491	P=0.113
POLY 6	P=0.018*	(e)	P=0.477	P=0.105
COCH-ARM / FISHERS	P=0.021*	(e)	P=0.500	P=0.121
MAX-ISO-POLY-3	P=0.023*	(e)	P=0.158	P=0.038*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/49 (2%)	3/50 (6%)
POLY-3 RATE (b)	0/46.64	1/46.01	1/42.54	3/44.14
POLY-3 PERCENT (g)	0%	2.2%	2.4%	6.8%
TERMINAL (d)	0/38 (0%)	1/37 (3%)	1/33 (3%)	3/37 (8%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.052	P=0.497	P=0.482	P=0.109
POLY 1.5	P=0.055	P=0.498	P=0.487	P=0.113
POLY 6	P=0.049*	P=0.497	P=0.475	P=0.105
COCH-ARM / FISHERS	P=0.058	P=0.500	P=0.495	P=0.121
MAX-ISO-POLY-3	P=0.042*	P=0.159	P=0.157	P=0.038*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Cyst**

LESION RATES

OVERALL (a)	18/50 (36%)	12/50 (24%)	14/49 (29%)	13/50 (26%)
POLY-3 RATE (b)	18/47.50	12/46.29	14/44.86	13/45.20
POLY-3 PERCENT (g)	37.9%	25.9%	31.2%	28.8%
TERMINAL (d)	15/38 (40%)	11/37 (30%)	10/33 (30%)	10/37 (27%)
FIRST INCIDENCE	619	652	442	584

STATISTICAL TESTS

POLY 3	P=0.307N	P=0.152N	P=0.324N	P=0.237N
POLY 1.5	P=0.289N	P=0.148N	P=0.306N	P=0.219N
POLY 6	P=0.326N	P=0.156N	P=0.350N	P=0.256N
COCH-ARM / FISHERS	P=0.265N	P=0.138N	P=0.283N	P=0.194N
MAX-ISO-POLY-3	P=0.277N	P=0.108N	P=0.255N	P=0.181N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	20/50 (40%)	20/50 (40%)	14/49 (29%)	19/50 (38%)
POLY-3 RATE (b)	20/47.80	20/47.06	14/43.86	19/45.68
POLY-3 PERCENT (g)	41.8%	42.5%	31.9%	41.6%
TERMINAL (d)	17/38 (45%)	16/37 (43%)	10/33 (30%)	15/37 (41%)
FIRST INCIDENCE	619	639	547	534

STATISTICAL TESTS

POLY 3	P=0.519N	P=0.557	P=0.220N	P=0.574N
POLY 1.5	P=0.490N	P=0.561	P=0.195N	P=0.544N
POLY 6	P=0.546	P=0.560	P=0.255N	P=0.566
COCH-ARM / FISHERS	P=0.453N	P=0.581N	P=0.162N	P=0.500N
MAX-ISO-POLY-3	P=0.483N	P=0.473	P=0.171N	P=0.490N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Intermedia
 Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/42.54	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Rathke's Cleft
 Cyst**

LESION RATES

OVERALL (a)	3/50 (6%)	1/50 (2%)	4/49 (8%)	0/50 (0%)
POLY-3 RATE (b)	3/46.64	1/46.27	4/43.16	0/44.14
POLY-3 PERCENT (g)	6.4%	2.2%	9.3%	0%
TERMINAL (d)	3/38 (8%)	0/37 (0%)	2/33 (6%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	659	592	---

STATISTICAL TESTS

POLY 3	P=0.160N	P=0.308N	P=0.458	P=0.129N
POLY 1.5	P=0.153N	P=0.308N	P=0.470	P=0.125N
POLY 6	P=0.168N	P=0.306N	P=0.445	P=0.133N
COCH-ARM / FISHERS	P=0.145N	P=0.309N	P=0.489	P=0.121N
MAX-ISO-POLY-3	P=0.114N	P=0.157N	P=0.315	P=0.046N*

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Skeletal Muscle
Fibrosis

LESION RATES

OVERALL (a)	0/0 (0%)	0/1 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/0.90	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin
 Cyst Epithelial Inclusion**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	1/46.01	0/43.15	1/44.14
POLY-3 PERCENT (g)	0%	2.2%	0%	2.3%
TERMINAL (d)	0/38 (0%)	1/37 (3%)	0/33 (0%)	1/37 (3%)
FIRST INCIDENCE	---	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.410	P=0.497	(e)	P=0.489
POLY 1.5	P=0.416	P=0.498	(e)	P=0.493
POLY 6	P=0.403	P=0.497	(e)	P=0.484
COCH-ARM / FISHERS	P=0.425	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.255	P=0.159	(e)	P=0.158

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin
Fibrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin
 Hyperkeratosis**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/46.64	1/46.01	0/43.15	2/44.14
POLY-3 PERCENT (g)	0%	2.2%	0%	4.5%
TERMINAL (d)	0/38 (0%)	1/37 (3%)	0/33 (0%)	2/37 (5%)
FIRST INCIDENCE	---	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.130	P=0.497	(e)	P=0.225
POLY 1.5	P=0.133	P=0.498	(e)	P=0.230
POLY 6	P=0.126	P=0.497	(e)	P=0.220
COCH-ARM / FISHERS	P=0.138	P=0.500	(e)	P=0.247
MAX-ISO-POLY-3	P=0.078	P=0.159	(e)	P=0.076

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Skin: Epidermis
 Hyperplasia

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Fibrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/45.33	1/43.93	0/44.14
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	442	---

STATISTICAL TESTS

POLY 3	P=0.773	(e)	P=0.488	(e)
POLY 1.5	P=0.779	(e)	P=0.493	(e)
POLY 6	P=0.765	(e)	P=0.481	(e)
COCH-ARM / FISHERS	P=0.788N	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.388	(e)	P=0.158	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	5/50 (10%)	3/49 (6%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	5/47.27	3/46.03	6/44.43	2/44.51
POLY-3 PERCENT (g)	10.6%	6.5%	13.5%	4.5%
TERMINAL (d)	2/38 (5%)	0/37 (0%)	3/33 (9%)	1/37 (3%)
FIRST INCIDENCE	619	652	547	625

STATISTICAL TESTS

POLY 3	P=0.250N	P=0.371N	P=0.457	P=0.241N
POLY 1.5	P=0.236N	P=0.372N	P=0.474	P=0.231N
POLY 6	P=0.267N	P=0.367N	P=0.436	P=0.253N
COCH-ARM / FISHERS	P=0.219N	P=0.369N	P=0.500	P=0.218N
MAX-ISO-POLY-3	P=0.256N	P=0.245N	P=0.338	P=0.144N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Hemorrhage**

LESION RATES

OVERALL (a)	0/50 (0%)	1/49 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	1/45.75	1/43.16	1/44.57
POLY-3 PERCENT (g)	0%	2.2%	2.3%	2.2%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	610	727	605

STATISTICAL TESTS

POLY 3	P=0.422	P=0.496	P=0.485	P=0.491
POLY 1.5	P=0.430	P=0.495	P=0.491	P=0.494
POLY 6	P=0.415	P=0.498	P=0.477	P=0.488
COCH-ARM / FISHERS	P=0.440	P=0.495	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.329	P=0.157	P=0.158	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Necrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/45.33	0/43.15	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Pigmentation**

LESION RATES

OVERALL (a)	43/50 (86%)	44/49 (90%)	39/50 (78%)	36/50 (72%)
POLY-3 RATE (b)	43/48.07	44/48.20	39/46.38	36/45.35
POLY-3 PERCENT (g)	89.5%	91.3%	84.1%	79.4%
TERMINAL (d)	38/38 (100%)	35/37 (95%)	31/33 (94%)	34/37 (92%)
FIRST INCIDENCE	619	337	547	510

STATISTICAL TESTS

POLY 3	P=0.046N*	P=0.518	P=0.303N	P=0.116N
POLY 1.5	P=0.029N*	P=0.459	P=0.264N	P=0.090N
POLY 6	P=0.092N	P=0.612	P=0.348N	P=0.175N
COCH-ARM / FISHERS	P=0.019N*	P=0.394	P=0.218N	P=0.070N
MAX-ISO-POLY-3	P=0.072N	P=0.370	P=0.201N	P=0.070N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen: Lymphoid Follicle
 Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	2/49 (4%)	3/50 (6%)	11/50 (22%)
POLY-3 RATE (b)	1/46.64	2/45.53	3/43.15	11/44.14
POLY-3 PERCENT (g)	2.1%	4.4%	7%	24.9%
TERMINAL (d)	1/38 (3%)	1/37 (3%)	3/33 (9%)	11/37 (30%)
FIRST INCIDENCE	729 (T)	679	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.492	P=0.278	P<0.001**
POLY 1.5	P<0.001**	P=0.491	P=0.289	P<0.001**
POLY 6	P<0.001**	P=0.495	P=0.264	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.492	P=0.309	P=0.002**
MAX-ISO-POLY-3	P<0.001**	P=0.275	P=0.145	P<0.001**

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Stomach, Forestomach
 Edema

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	1/46.64	3/46.68	2/43.75	3/45.88
POLY-3 PERCENT (g)	2.1%	6.4%	4.6%	6.5%
TERMINAL (d)	1/38 (3%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	652	641	534

STATISTICAL TESTS

POLY 3	P=0.316	P=0.306	P=0.478	P=0.299
POLY 1.5	P=0.320	P=0.304	P=0.487	P=0.302
POLY 6	P=0.313	P=0.310	P=0.468	P=0.298
COCH-ARM / FISHERS	P=0.324	P=0.309	P=0.500	P=0.309
MAX-ISO-POLY-3	P=0.268	P=0.154	P=0.268	P=0.152

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach
 Ulcer**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/47.03	2/46.58	2/43.94	2/45.21
POLY-3 PERCENT (g)	4.3%	4.3%	4.6%	4.4%
TERMINAL (d)	1/38 (3%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	619	652	575	547

STATISTICAL TESTS

POLY 3	P=0.595	P=0.690	P=0.669	P=0.680
POLY 1.5	P=0.603	P=0.690	P=0.679	P=0.685
POLY 6	P=0.587	P=0.692	P=0.658	P=0.674
COCH-ARM / FISHERS	P=0.614	P=0.691N	P=0.691N	P=0.691N
MAX-ISO-POLY-3	P=0.724	P=0.495	P=0.472	P=0.484

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	1/50 (2%)	2/50 (4%)	6/50 (12%)
POLY-3 RATE (b)	3/47.03	1/46.24	2/43.75	6/46.36
POLY-3 PERCENT (g)	6.4%	2.2%	4.6%	12.9%
TERMINAL (d)	2/38 (5%)	0/37 (0%)	0/33 (0%)	2/37 (5%)
FIRST INCIDENCE	619	668	641	534

STATISTICAL TESTS

POLY 3	P=0.063	P=0.311N	P=0.533N	P=0.235
POLY 1.5	P=0.064	P=0.310N	P=0.519N	P=0.238
POLY 6	P=0.062	P=0.312N	P=0.548N	P=0.233
COCH-ARM / FISHERS	P=0.065	P=0.309N	P=0.500N	P=0.243
MAX-ISO-POLY-3	P=0.069	P=0.161N	P=0.358N	P=0.143

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular
 Edema**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	2/45.07
POLY-3 PERCENT (g)	0%	0%	0%	4.4%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	547

STATISTICAL TESTS

POLY 3	P=0.041*	(e)	(e)	P=0.230
POLY 1.5	P=0.042*	(e)	(e)	P=0.233
POLY 6	P=0.041*	(e)	(e)	P=0.227
COCH-ARM / FISHERS	P=0.044*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.033*	(e)	(e)	P=0.076

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular
 Erosion**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	3/45.68
POLY-3 PERCENT (g)	0%	0%	0%	6.6%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	534

STATISTICAL TESTS

POLY 3	P=0.009**	(e)	(e)	P=0.115
POLY 1.5	P=0.009**	(e)	(e)	P=0.116
POLY 6	P=0.009**	(e)	(e)	P=0.114
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	P=0.121
MAX-ISO-POLY-3	P=0.009**	(e)	(e)	P=0.038*

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular
 Ulcer**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	0/46.01	2/44.31	1/44.49
POLY-3 PERCENT (g)	0%	0%	4.5%	2.3%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	442	632

STATISTICAL TESTS

POLY 3	P=0.302	(e)	P=0.226	P=0.491
POLY 1.5	P=0.310	(e)	P=0.231	P=0.494
POLY 6	P=0.295	(e)	P=0.220	P=0.487
COCH-ARM / FISHERS	P=0.320	(e)	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.172	(e)	P=0.076	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/46.64	2/46.29	0/43.15	1/44.14
POLY-3 PERCENT (g)	2.1%	4.3%	0%	2.3%
TERMINAL (d)	1/38 (3%)	1/37 (3%)	0/33 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	652	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.565N	P=0.497	P=0.516N	P=0.748
POLY 1.5	P=0.560N	P=0.497	P=0.509N	P=0.753
POLY 6	P=0.571N	P=0.499	P=0.523N	P=0.743
COCH-ARM / FISHERS	P=0.554N	P=0.500	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.413N	P=0.279	P=0.177N	P=0.484

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thymus
 Atrophy**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/42.66	1/44.14
POLY-3 PERCENT (g)	0%	0%	0%	2.3%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	1/37 (3%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.205	(e)	(e)	P=0.489
POLY 1.5	P=0.208	(e)	(e)	P=0.493
POLY 6	P=0.201	(e)	(e)	P=0.484
COCH-ARM / FISHERS	P=0.211	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.125	(e)	(e)	P=0.158

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Thymus
Hyperplasia Lymphoid

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/42.66	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

.....
STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland
 Ultimobranchial Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	0/46.01	2/43.15	1/44.56
POLY-3 PERCENT (g)	0%	0%	4.6%	2.2%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	2/33 (6%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	610

STATISTICAL TESTS

POLY 3	P=0.303	(e)	P=0.220	P=0.491
POLY 1.5	P=0.310	(e)	P=0.227	P=0.494
POLY 6	P=0.296	(e)	P=0.212	P=0.488
COCH-ARM / FISHERS	P=0.320	(e)	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.166	(e)	P=0.076	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: C-Cell
 Hyperplasia**

LESION RATES

OVERALL (a)	27/50 (54%)	33/50 (66%)	24/50 (48%)	25/50 (50%)
POLY-3 RATE (b)	27/47.42	33/47.25	24/45.12	25/45.10
POLY-3 PERCENT (g)	56.9%	69.8%	53.2%	55.4%
TERMINAL (d)	21/38 (55%)	28/37 (76%)	18/33 (55%)	23/37 (62%)
FIRST INCIDENCE	688	610	547	534

STATISTICAL TESTS

POLY 3	P=0.296N	P=0.133	P=0.438N	P=0.526N
POLY 1.5	P=0.255N	P=0.136	P=0.399N	P=0.480N
POLY 6	P=0.359N	P=0.134	P=0.487N	P=0.585N
COCH-ARM / FISHERS	P=0.213N	P=0.154	P=0.345N	P=0.421N
MAX-ISO-POLY-3	P=0.302N	P=0.092	P=0.359N	P=0.441N

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: Follicle
 Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/46.64	1/46.01	2/43.72	1/44.56
POLY-3 PERCENT (g)	0%	2.2%	4.6%	2.2%
TERMINAL (d)	0/38 (0%)	1/37 (3%)	1/33 (3%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	552	610

STATISTICAL TESTS

POLY 3	P=0.425	P=0.497	P=0.223	P=0.491
POLY 1.5	P=0.433	P=0.498	P=0.229	P=0.494
POLY 6	P=0.416	P=0.497	P=0.216	P=0.488
COCH-ARM / FISHERS	P=0.446	P=0.500	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.226	P=0.159	P=0.076	P=0.158

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: Follicular Cell
 Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/46.64	0/46.01	0/43.15	0/44.14
POLY-3 PERCENT (g)	2.1%	0%	0%	0%
TERMINAL (d)	1/38 (3%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.390N	P=0.503N	P=0.516N	P=0.511N
POLY 1.5	P=0.391N	P=0.502N	P=0.509N	P=0.507N
POLY 6	P=0.390N	P=0.503N	P=0.523N	P=0.516N
COCH-ARM / FISHERS	P=0.394N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.143N	P=0.162N	P=0.177N	P=0.172N

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Tongue
Hyperplasia

LESION RATES

OVERALL (a)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/1 (0%)
POLY-3 RATE (b)	0/1.00	0/0.00	0/1.00	0/0.51
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Urinary Bladder: Transitional Epithelium
Hyperplasia

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	0/43.15	0/44.14
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Uterus
 Hyperplasia Cystic**

LESION RATES

OVERALL (a)	9/50 (18%)	8/50 (16%)	11/50 (22%)	14/50 (28%)
POLY-3 RATE (b)	9/47.31	8/46.71	11/43.98	14/46.05
POLY-3 PERCENT (g)	19%	17.1%	25%	30.4%
TERMINAL (d)	6/38 (16%)	7/37 (19%)	8/33 (24%)	10/37 (27%)
FIRST INCIDENCE	619	485	619	534

STATISTICAL TESTS

POLY 3	P=0.076	P=0.511N	P=0.331	P=0.149
POLY 1.5	P=0.081	P=0.508N	P=0.360	P=0.158
POLY 6	P=0.071	P=0.516N	P=0.299	P=0.141
COCH-ARM / FISHERS	P=0.089	P=0.500N	P=0.402	P=0.171
MAX-ISO-POLY-3	P=0.119	P=0.405N	P=0.253	P=0.103

TDMS No. 99024 - 07
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 07/18/2008
 Time Report Requested: 13:49:10
 First Dose M/F: 02/03/03 / 02/03/03
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Uterus: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/46.64	0/46.01	2/44.19	0/44.14
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/38 (0%)	0/37 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	547	---

STATISTICAL TESTS

POLY 3	P=0.694	(e)	P=0.225	(e)
POLY 1.5	P=0.703	(e)	P=0.230	(e)
POLY 6	P=0.683	(e)	P=0.220	(e)
COCH-ARM / FISHERS	P=0.716	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.252	(e)	P=0.076	(e)

TDMS No. 99024 - 07
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Androstenedione
CAS Number: 63-05-8

Date Report Requested: 07/18/2008
Time Report Requested: 13:49:10
First Dose M/F: 02/03/03 / 02/03/03
Lab: SRI

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
 - (e) Value of Statistic cannot be computed.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***